BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 651] [Article Influence: 80.0] [Reference Citation Analysis]
Number Citing Articles
1 Sarnecka AK, Zagozda M, Durlik M. An Overview of Genetic Changes and Risk of Pancreatic Ductal Adenocarcinoma. J Cancer 2016;7:2045-51. [PMID: 27877219 DOI: 10.7150/jca.15323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
2 Srinivasan K, Subramanian T, Spielmann HP, Janetopoulos C. Identification of a farnesol analog as a Ras function inhibitor using both an in vivo Ras activation sensor and a phenotypic screening approach. Mol Cell Biochem 2014;387:177-86. [PMID: 24194124 DOI: 10.1007/s11010-013-1883-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Swami P, O'Connell KA, Thiyagarajan S, Crawford A, Patil P, Radhakrishnan P, Shin S, Caffrey TC, Grunkemeyer J, Neville T, Vetter SW, Hollingsworth MA, Leclerc E. Inhibition of the Receptor for Advanced Glycation End Products Enhances the Cytotoxic Effect of Gemcitabine in Murine Pancreatic Tumors. Biomolecules 2021;11:526. [PMID: 33915939 DOI: 10.3390/biom11040526] [Reference Citation Analysis]
4 Hasan N, Ahuja N. The Emerging Roles of ATP-Dependent Chromatin Remodeling Complexes in Pancreatic Cancer. Cancers (Basel) 2019;11:E1859. [PMID: 31769422 DOI: 10.3390/cancers11121859] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Wang S, Chen X, Tang M. Quantitative assessment of the diagnostic role of MUC1 in pancreatic ductal adenocarcinoma. Tumour Biol 2014;35:9101-9. [PMID: 25027396 DOI: 10.1007/s13277-014-2186-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
6 Saraee A, Vahedian-Ardakani J, Saraee E, Pakzad R, Wadji MB. Whipple procedure: a review of a 7-year clinical experience in a referral center for hepatobiliary and pancreas diseases. World J Surg Oncol 2015;13:98. [PMID: 25885408 DOI: 10.1186/s12957-015-0523-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
7 Delpu Y, Lulka H, Sicard F, Saint-Laurent N, Lopez F, Hanoun N, Buscail L, Cordelier P, Torrisani J. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool. PLoS One. 2013;8:e55513. [PMID: 23383211 DOI: 10.1371/journal.pone.0055513] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
8 Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM, Hollerbach S, Merger M, Munzert G, Fleischer F, Scheulen ME. A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. Br J Cancer 2012;107:280-6. [PMID: 22699824 DOI: 10.1038/bjc.2012.257] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
9 Beaty RM, Gronborg M, Pollack JR, Maitra A. Target discovery and validation in pancreatic cancer. Methods Mol Biol 2007;360:57-89. [PMID: 17172725 DOI: 10.1385/1-59745-165-7:57] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Lai M, Ge Y, Chen M, Sun S, Chen J, Cheng R. Saikosaponin D Inhibits Proliferation and Promotes Apoptosis Through Activation of MKK4-JNK Signaling Pathway in Pancreatic Cancer Cells. Onco Targets Ther 2020;13:9465-79. [PMID: 33061432 DOI: 10.2147/OTT.S263322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
11 Yang Y, Bai YS, Wang Q. CDGSH Iron Sulfur Domain 2 Activates Proliferation and EMT of Pancreatic Cancer Cells via Wnt/β-Catenin Pathway and Has Prognostic Value in Human Pancreatic Cancer. Oncol Res 2017;25:605-15. [PMID: 27983920 DOI: 10.3727/096504016X14767450526417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
12 Su JJ, Xu K, Wang PF, Zhang HY, Chen YL. Histological analysis of human pancreatic carcinoma following irreversible electroporation in a nude mouse model. World J Gastrointest Oncol 2018;10:476-86. [PMID: 30595801 DOI: 10.4251/wjgo.v10.i12.476] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Chan PC, Chang WL, Hsu MH, Yeh CH, Muo CH, Chang KS, Hsu CY, Wu BT, Lai CH, Lee CH, Ting H, Sung FC. Higher stroke incidence in the patients with pancreatic cancer: A nation-based cohort study in Taiwan. Medicine (Baltimore) 2018;97:e0133. [PMID: 29538211 DOI: 10.1097/MD.0000000000010133] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tang L, Ji M, Liang X, Chen D, Liu A, Yang G, Shi L, Fu Z, Shao C. Downregulated F-Box/LRR-Repeat Protein 7 Facilitates Pancreatic Cancer Metastasis by Regulating Snail1 for Proteasomal Degradation. Front Genet 2021;12:650090. [PMID: 34249081 DOI: 10.3389/fgene.2021.650090] [Reference Citation Analysis]
15 Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak MN, Fuchs CS. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer 2007;97:98-104. [PMID: 17533398 DOI: 10.1038/sj.bjc.6603826] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
16 Li Z, Lin P, Gao C, Peng C, Liu S, Gao H, Wang B, Wang J, Niu J, Niu W. Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC). Tumour Biol 2016;37:5117-31. [PMID: 26547582 DOI: 10.1007/s13277-015-4353-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
17 Heinrich S, Goerres GW, Schäfer M, Sagmeister M, Bauerfeind P, Pestalozzi BC, Hany TF, von Schulthess GK, Clavien PA. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005;242:235-243. [PMID: 16041214 DOI: 10.1097/01.sla.0000172095.97787.84] [Cited by in Crossref: 225] [Cited by in F6Publishing: 171] [Article Influence: 14.1] [Reference Citation Analysis]
18 Wu MY, Liang RR, Chen K, Shen M, Tian YL, Li DM, Duan WM, Gui Q, Gong FR, Lian L, Li W, Tao M. FH535 inhibited metastasis and growth of pancreatic cancer cells. Onco Targets Ther 2015;8:1651-70. [PMID: 26185454 DOI: 10.2147/OTT.S82718] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
19 Chen H, Sun B, Wang S, Pan S, Gao Y, Bai X, Xue D. Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB. J Cancer Res Clin Oncol 2010;136:897-903. [PMID: 19941148 DOI: 10.1007/s00432-009-0731-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
20 Ikuta Y, Takamori H, Sakamoto Y, Hashimoto D, Chikamoto A, Kuroki H, Sakata K, Sakamoto K, Hayashi H, Imai K, Nitta H, Hirota M, Kanemitsu K, Beppu T, Baba H. The modified Glasgow Prognostic Score (mGPS) is a good predictor of indication for palliative bypass surgery in patients with unresectable pancreatic and biliary cancers. Int J Clin Oncol 2014;19:629-33. [PMID: 23999903 DOI: 10.1007/s10147-013-0613-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wang T, Chen G, Ma X, Yang Y, Chen Y, Peng Y, Bai Z, Zhang Z, Pei H, Guo W. MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway. Cell Death Dis 2019;10:153. [PMID: 30770779 DOI: 10.1038/s41419-019-1326-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
22 Sorio C, Mafficini A, Furlan F, Barbi S, Bonora A, Brocco G, Blasi F, Talamini G, Bassi C, Scarpa A. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer 2011;11:448. [PMID: 21999221 DOI: 10.1186/1471-2407-11-448] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
23 La Torre G, Sferrazza A, Gualano MR, de Waure C, Clemente G, De Rose AM, Nicolotti N, Nuzzo G, Siliquini R, Boccia A, Ricciardi W. Investigating the synergistic interaction of diabetes, tobacco smoking, alcohol consumption, and hypercholesterolemia on the risk of pancreatic cancer: a case-control study in Italy. Biomed Res Int. 2014;2014:481019. [PMID: 24877100 DOI: 10.1155/2014/481019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
24 Abiatari I, Kleeff J, Li J, Felix K, Büchler MW, Friess H. Hsulf-1 regulates growth and invasion of pancreatic cancer cells. J Clin Pathol 2006;59:1052-8. [PMID: 16603650 DOI: 10.1136/jcp.2005.031716] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
25 Ishizaki H, Manuel ER, Song GY, Srivastava T, Sun S, Diamond DJ, Ellenhorn JD. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother. 2011;60:99-109. [PMID: 20960189 DOI: 10.1007/s00262-010-0923-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
26 Fulda S. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J Cell Mol Med 2009;13:1221-7. [PMID: 19382915 DOI: 10.1111/j.1582-4934.2009.00748.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
27 Babic A, Schnure N, Neupane NP, Zaman MM, Rifai N, Welch MW, Brais LK, Rubinson DA, Morales-Oyarvide V, Yuan C, Zhang S, Poole EM, Wolpin BM, Kulke MH, Barbie DA, Wong K, Fuchs CS, Ng K. Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol 2018;9:145. [PMID: 29691365 DOI: 10.1038/s41424-018-0008-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
28 Wang L, Dong P, Wang W, Huang M, Tian B. Gemcitabine treatment causes resistance and malignancy of pancreatic cancer stem-like cells via induction of lncRNA HOTAIR. Exp Ther Med 2017;14:4773-80. [PMID: 29201179 DOI: 10.3892/etm.2017.5151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
29 Yang C, Yu T, Liu Z, Ye X, Liao X, Wang X, Han C, Zhu G, Qin W, Peng T. Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for early‑stage pancreatic ductal adenocarcinoma. Oncol Rep 2019;42:79-90. [PMID: 31059105 DOI: 10.3892/or.2019.7135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
30 Rajurkar M, De Jesus-Monge WE, Driscoll DR, Appleman VA, Huang H, Cotton JL, Klimstra DS, Zhu LJ, Simin K, Xu L, McMahon AP, Lewis BC, Mao J. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc Natl Acad Sci U S A 2012;109:E1038-47. [PMID: 22493246 DOI: 10.1073/pnas.1114168109] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 9.0] [Reference Citation Analysis]
31 Batista V, Richter D, Combs SE, Jäkel O. Planning strategies for inter-fractional robustness in pancreatic patients treated with scanned carbon therapy. Radiat Oncol 2017;12:94. [PMID: 28595643 DOI: 10.1186/s13014-017-0832-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
32 Liu-Mares W, Mackinnon JA, Sherman R, Fleming LE, Rocha-Lima C, Hu JJ, Lee DJ. Pancreatic cancer clusters and arsenic-contaminated drinking water wells in Florida. BMC Cancer 2013;13:111. [PMID: 23510413 DOI: 10.1186/1471-2407-13-111] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
33 Kang CM, Lee SH, Hwang HK, Yun M, Lee WJ. Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer. Medicine (Baltimore) 2016;95:e2595. [PMID: 26945350 DOI: 10.1097/MD.0000000000002595] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
34 Zhang J, Zuo CJ, Jia NY, Wang JH, Hu SP, Yu ZF, Zheng Y, Zhang AY, Feng XY. Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer. World J Gastroenterol. 2015;21:2988-2996. [PMID: 25780297 DOI: 10.3748/wjg.v21.i10.2988] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
35 Cheng P, Chen Y, He TL, Wang C, Guo SW, Hu H, Ni CM, Jin G, Zhang YJ. Menin Coordinates C/EBPβ-Mediated TGF-β Signaling for Epithelial-Mesenchymal Transition and Growth Inhibition in Pancreatic Cancer. Mol Ther Nucleic Acids 2019;18:155-65. [PMID: 31546150 DOI: 10.1016/j.omtn.2019.08.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
36 Takatori K, Terashima K, Yoshida R, Horai A, Satake S, Ose T, Kitajima N, Kinoshita Y, Demizu Y, Fuwa N. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. J Gastroenterol. 2014;49:1074-1080. [PMID: 23846547 DOI: 10.1007/s00535-013-0857-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
37 Elnahal SM, Shinagare AB, Szymonifka J, Hong TS, Enzinger PC, Mamon HJ. Prevalence and significance of subcentimeter hepatic lesions in patients with localized pancreatic adenocarcinoma. Pract Radiat Oncol 2012;2:e89-94. [PMID: 24674191 DOI: 10.1016/j.prro.2012.02.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
38 Miyatake Y, Kuribayashi-Shigetomi K, Ohta Y, Ikeshita S, Subagyo A, Sueoka K, Kakugo A, Amano M, Takahashi T, Okajima T, Kasahara M. Visualising the dynamics of live pancreatic microtumours self-organised through cell-in-cell invasion. Sci Rep 2018;8:14054. [PMID: 30232338 DOI: 10.1038/s41598-018-32122-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
39 Wang S, Zhao P, Cao B. Development and optimization of an antibody array method for potential cancer biomarker detection. J Biomed Res 2011;25:63-70. [PMID: 23554673 DOI: 10.1016/S1674-8301(11)60008-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Jorand R, Biswas S, Wakefield DL, Tobin SJ, Golfetto O, Hilton K, Ko M, Ramos JW, Small AR, Chu P, Singh G, Jovanovic-Talisman T. Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer. Mol Biol Cell 2016;27:3659-72. [PMID: 27682590 DOI: 10.1091/mbc.E16-06-0427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
41 Li L, Zhang JW, Jenkins G, Xie F, Carlson EE, Fridley BL, Bamlet WR, Petersen GM, McWilliams RR, Wang L. Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer. Pharmacogenet Genomics 2016;26:527-37. [PMID: 27749787 DOI: 10.1097/FPC.0000000000000241] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
42 Słotwiński R, Słotwińska SM. Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer. Cent Eur J Immunol 2016;41:392-403. [PMID: 28450803 DOI: 10.5114/ceji.2016.65139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
43 Şahin Aker S, Katlan DC, Yüce T, Söylemez F. Placental, hepatic, and supraclavicular lymph node metastasis in pancreatic adenocarcinoma during pregnancy: A case report. Turk J Obstet Gynecol 2016;13:161-3. [PMID: 28913114 DOI: 10.4274/tjod.39327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Koorstra JB, Feldmann G, Habbe N, Maitra A. Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs). Langenbecks Arch Surg 2008;393:561-70. [PMID: 18283486 DOI: 10.1007/s00423-008-0282-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
45 Mehta KY, Wu HJ, Menon SS, Fallah Y, Zhong X, Rizk N, Unger K, Mapstone M, Fiandaca MS, Federoff HJ, Cheema AK. Metabolomic biomarkers of pancreatic cancer: a meta-analysis study. Oncotarget. 2017;8:68899-68915. [PMID: 28978166 DOI: 10.18632/oncotarget.20324] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 8.5] [Reference Citation Analysis]
46 Leask A. CCN1: a novel target for pancreatic cancer. J Cell Commun Signal 2011;5:123-4. [PMID: 21484184 DOI: 10.1007/s12079-011-0127-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
47 Lei J, Wu Z, Jiang Z, Li J, Zong L, Chen X, Duan W, Xu Q, Zhang L, Han L, Ma Q, Wang Z, Zhang D. Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells. Oncotarget 2016;7:83601-10. [PMID: 27876704 DOI: 10.18632/oncotarget.13469] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
48 Spiliotis JD, Datsis AC, Michalopoulos NV, Kekelos SP, Vaxevanidou A, Rogdakis AG, Christopoulou AN. Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas. Langenbecks Arch Surg. 2007;392:55-60. [PMID: 17089173 DOI: 10.1007/s00423-006-0098-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 5.1] [Reference Citation Analysis]
49 Torres PJ, Fletcher EM, Gibbons SM, Bouvet M, Doran KS, Kelley ST. Characterization of the salivary microbiome in patients with pancreatic cancer. PeerJ. 2015;3:e1373. [PMID: 26587342 DOI: 10.7717/peerj.1373] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 12.8] [Reference Citation Analysis]
50 Jeong Y, Lim JW, Kim H. Lycopene Inhibits Reactive Oxygen Species-Mediated NF-κB Signaling and Induces Apoptosis in Pancreatic Cancer Cells. Nutrients 2019;11:E762. [PMID: 30939781 DOI: 10.3390/nu11040762] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
51 Huang X, Zheng J, Li J, Che X, Tan W, Tan W, Shao M, Cheng X, Du Z, Zhao Y, Wang C, Wu C, Lin D. Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine. Theranostics 2018;8:3366-79. [PMID: 29930735 DOI: 10.7150/thno.23978] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
52 Xu X, Rao GS, Groh V, Spies T, Gattuso P, Kaufman HL, Plate J, Prinz RA. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer 2011;11:194. [PMID: 21605422 DOI: 10.1186/1471-2407-11-194] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
53 Johnson BA 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin Cancer Res. 2017;23:1656-1669. [PMID: 28373364 DOI: 10.1158/1078-0432.ccr-16-2318] [Cited by in Crossref: 68] [Cited by in F6Publishing: 41] [Article Influence: 22.7] [Reference Citation Analysis]
54 Arundhathi A, Chuang WH, Chen JK, Wang SE, Shyr YM, Chen JY, Liao WN, Chen HW, Teng YM, Pai CC, Wang CH. Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis. Oncotarget 2016;7:55437-48. [PMID: 28874965 DOI: 10.18632/oncotarget.10583] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
55 Gaida MM, Bach ST, Günther F, Baseras B, Tschaharganeh DF, Welsch T, Felix K, Bergmann F, Hänsch GM, Wente MN. Expression of galectin-3 in pancreatic ductal adenocarcinoma. Pathol Oncol Res 2012;18:299-307. [PMID: 21910036 DOI: 10.1007/s12253-011-9444-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
56 Hamada S, Satoh K, Kimura K, Kanno A, Masamune A, Shimosegawa T. MSX2 overexpression inhibits gemcitabine-induced caspase-3 activity in pancreatic cancer cells. World J Gastroenterol 2005;11:6867-70. [PMID: 16425399 DOI: 10.3748/wjg.v11.i43.6867] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
57 Jäkel CE, Vogt A, Gonzalez-Carmona MA, Schmidt-Wolf IG. Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res 2014;2014:897214. [PMID: 24741629 DOI: 10.1155/2014/897214] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
58 Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457-1461. [PMID: 19460966 DOI: 10.1126/science.1171362] [Cited by in Crossref: 2060] [Cited by in F6Publishing: 1912] [Article Influence: 171.7] [Reference Citation Analysis]
59 Wang S, Yang J, Ding C, Li J, You L, Dai M, Zhao Y. Glutathione S-Transferase Mu-3 Predicts a Better Prognosis and Inhibits Malignant Behavior and Glycolysis in Pancreatic Cancer. Front Oncol 2020;10:1539. [PMID: 32984010 DOI: 10.3389/fonc.2020.01539] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 di Sebastiano P, Grottola T, di Mola FF. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy. Updates Surg. 2016;68:235-239. [PMID: 27629483 DOI: 10.1007/s13304-016-0392-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
61 Nelson SR, Walsh N. Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients. Cancers (Basel) 2020;12:E1233. [PMID: 32423157 DOI: 10.3390/cancers12051233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Chen D, Wu X, Zhao J, Zhao X. MicroRNA-634 functions as a tumor suppressor in pancreatic cancer via directly targeting heat shock-related 70-kDa protein 2. Exp Ther Med 2019;17:3949-56. [PMID: 30988777 DOI: 10.3892/etm.2019.7433] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
63 Wang P, Zhu Z. Prognostic and Clinicopathological Significance of E-Cadherin in Pancreatic Cancer Patients: A Meta-Analysis. Front Oncol 2021;11:627116. [PMID: 33912451 DOI: 10.3389/fonc.2021.627116] [Reference Citation Analysis]
64 Stenzinger A, Endris V, Klauschen F, Sinn B, Lorenz K, Warth A, Goeppert B, Ehemann V, Muckenhuber A, Kamphues C, Bahra M, Neuhaus P, Weichert W. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC Cancer 2013;13:450. [PMID: 24088390 DOI: 10.1186/1471-2407-13-450] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
65 Chao YJ, Sy ED, Hsu HP, Shan YS. Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy. BMC Surg 2014;14:72. [PMID: 25258022 DOI: 10.1186/1471-2482-14-72] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
66 Bachireddy P, Tseng D, Horoschak M, Chang DT, Koong AC, Kapp DS, Tran PT. Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. Radiat Oncol 2010;5:105. [PMID: 21059255 DOI: 10.1186/1748-717X-5-105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Chaudhary S, Sun SY. Endoscopic ultrasound-guided radiofrequency ablation in gastroenterology: New horizons in search. World J Gastroenterol. 2017;23:4892-4896. [PMID: 28785143 DOI: 10.3748/wjg.v23.i27.4892] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Byrne JD, Jajja MR, O'Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM. Local iontophoretic administration of cytotoxic therapies to solid tumors. Sci Transl Med 2015;7:273ra14. [PMID: 25653220 DOI: 10.1126/scitranslmed.3009951] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
69 Chen YK. Pancreatoscopy: present and future role. Curr Gastroenterol Rep 2007;9:136-43. [PMID: 17418059 DOI: 10.1007/s11894-007-0008-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
70 Rong Y, Jin D, Hou C, Hu J, Wu W, Ni X, Wang D, Lou W. Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2. BMC Gastroenterol 2010;10:68. [PMID: 20587030 DOI: 10.1186/1471-230X-10-68] [Cited by in Crossref: 41] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
71 Yu C, Zhang X, Sun G, Guo X, Li H, You Y, Jacobs JL, Gardner K, Yuan D, Xu Z, Du Q, Dai C, Qian Z, Jiang K, Zhu Y, Li QQ, Miao Y. RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells. J Cell Mol Med 2008;12:2334-49. [PMID: 18266952 DOI: 10.1111/j.1582-4934.2008.00257.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
72 Batty GD, Kivimaki M, Morrison D, Huxley R, Smith GD, Clarke R, Marmot MG, Shipley MJ. Risk factors for pancreatic cancer mortality: extended follow-up of the original Whitehall Study. Cancer Epidemiol Biomarkers Prev. 2009;18:673-675. [PMID: 19190162 DOI: 10.1158/1055-9965.epi-08-1032] [Cited by in Crossref: 50] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
73 Shen Q, Yu M, Jia JK, Li WX, Tian YW, Xue HZ. Possible Molecular Markers for the Diagnosis of Pancreatic Ductal Adenocarcinoma. Med Sci Monit 2018;24:2368-76. [PMID: 29671412 DOI: 10.12659/msm.906313] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
74 Abbas W, Kumar A, Herbein G. The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral Infections. Front Oncol 2015;5:75. [PMID: 25905039 DOI: 10.3389/fonc.2015.00075] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 13.8] [Reference Citation Analysis]
75 Gordon KJ, Kirkbride KC, How T, Blobe GC. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis. 2009;30:238-248. [PMID: 19056927 DOI: 10.1093/carcin/bgn274] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 5.8] [Reference Citation Analysis]
76 Tahkola K, Mecklin JP, Wirta EV, Ahtiainen M, Helminen O, Böhm J, Kellokumpu I. High immune cell score predicts improved survival in pancreatic cancer. Virchows Arch 2018;472:653-65. [PMID: 29356891 DOI: 10.1007/s00428-018-2297-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
77 Nipp RD, Tramontano AC, Kong CY, Hur C. Patterns and predictors of end-of-life care in older patients with pancreatic cancer. Cancer Med 2018;7:6401-10. [PMID: 30426697 DOI: 10.1002/cam4.1861] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
78 Chen X, Liao J, Lu Y, Duan X, Sun W. Activation of the PI3K/Akt pathway mediates bone morphogenetic protein 2-induced invasion of pancreatic cancer cells Panc-1. Pathol Oncol Res 2011;17:257-61. [PMID: 20848249 DOI: 10.1007/s12253-010-9307-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
79 Song W, Miao DL, Chen L. Nomogram for predicting survival in patients with pancreatic cancer. Onco Targets Ther 2018;11:539-45. [PMID: 29416354 DOI: 10.2147/OTT.S154599] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
80 Marzoq AJ, Giese N, Hoheisel JD, Alhamdani MS. Proteome variations in pancreatic stellate cells upon stimulation with proinflammatory factors. J Biol Chem. 2013;288:32517-32527. [PMID: 24089530 DOI: 10.1074/jbc.m113.488387] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
81 Wang H, Mislati R, Ahmed R, Vincent P, Nwabunwanne SF, Gunn JR, Pogue BW, Doyley MM. Elastography Can Map the Local Inverse Relationship between Shear Modulus and Drug Delivery within the Pancreatic Ductal Adenocarcinoma Microenvironment. Clin Cancer Res 2019;25:2136-43. [PMID: 30352906 DOI: 10.1158/1078-0432.CCR-18-2684] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
82 Reul NK, Li W, Gallagher LG, Ray RM, Romano ME, Gao D, Thomas DB, Vedal S, Checkoway H. Risk of Pancreatic Cancer in Female Textile Workers in Shanghai, China, Exposed to Metals, Solvents, Chemicals, and Endotoxin: Follow-Up to a Nested Case-Cohort Study. J Occup Environ Med 2016;58:195-9. [PMID: 26849264 DOI: 10.1097/JOM.0000000000000596] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Wang X, Lu X, Zhang T, Wen C, Shi M, Tang X, Chen H, Peng C, Li H, Fang Y, Deng X, Shen B. mir-329 restricts tumor growth by targeting grb2 in pancreatic cancer. Oncotarget 2016;7:21441-53. [PMID: 26885689 DOI: 10.18632/oncotarget.7375] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
84 Li C, Xin W, Sy MS. Binding of pro-prion to filamin A: by design or an unfortunate blunder. Oncogene 2010;29:5329-45. [PMID: 20697352 DOI: 10.1038/onc.2010.307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
85 Fridley BL, Jenkins G, Schaid DJ, Wang L. A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity. Stat Med 2009;28:2709-22. [PMID: 19572260 DOI: 10.1002/sim.3649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
86 Lewandowski RJ, Eifler AC, Bentrem DJ, Chung JC, Wang D, Woloschak GE, Yang GY, Ryu R, Salem R, Larson AC, Omary RA. Functional magnetic resonance imaging in an animal model of pancreatic cancer. World J Gastroenterol 2010;16:3292-8. [PMID: 20614485 DOI: 10.3748/wjg.v16.i26.3292] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
87 Ge G, Wong GW. Classification of premalignant pancreatic cancer mass-spectrometry data using decision tree ensembles. BMC Bioinformatics 2008;9:275. [PMID: 18547427 DOI: 10.1186/1471-2105-9-275] [Cited by in Crossref: 55] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
88 Zou W, She J, Tolstikov VV. A comprehensive workflow of mass spectrometry-based untargeted metabolomics in cancer metabolic biomarker discovery using human plasma and urine. Metabolites 2013;3:787-819. [PMID: 24958150 DOI: 10.3390/metabo3030787] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
89 Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene 2013;32:5253-60. [PMID: 23416985 DOI: 10.1038/onc.2013.29] [Cited by in Crossref: 120] [Cited by in F6Publishing: 94] [Article Influence: 15.0] [Reference Citation Analysis]
90 Hu S, Jin Y, Liu Y, Ljungman M, Neamati N. Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines. Eur J Med Chem 2018;158:884-95. [PMID: 30253345 DOI: 10.1016/j.ejmech.2018.09.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
91 Combs SE, Habermehl D, Kieser M, Dreher C, Werner J, Haselmann R, Jäkel O, Jäger D, Büchler MW, Debus J. Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial. BMC Cancer 2013;13:419. [PMID: 24034562 DOI: 10.1186/1471-2407-13-419] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
92 Zhou Y, Hua Z, Zhu Y, Wang L, Chen F, Shan T, Zhou Y, Dai T. Upregulation of ARHGAP30 attenuates pancreatic cancer progression by inactivating the β-catenin pathway. Cancer Cell Int 2020;20:225. [PMID: 32536813 DOI: 10.1186/s12935-020-01288-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
93 Ferretti E, Pistoia V, Corcione A. Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies. Mediators Inflamm 2014;2014:480941. [PMID: 24799766 DOI: 10.1155/2014/480941] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
94 Tinkl D, Grabenbauer GG, Golcher H, Meyer T, Papadopoulos T, Hohenberger W, Sauer R, Brunner TB. Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol. 2009;185:557-566. [PMID: 19756421 DOI: 10.1007/s00066-009-1977-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
95 Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Yoshida Y, Tanaka M, Uesaka K. Prognostic Scoring System for Patients Who Present with a Gastric Outlet Obstruction Caused by Advanced Pancreatic Adenocarcinoma. World J Surg 2017;41:2619-24. [PMID: 28439647 DOI: 10.1007/s00268-017-4027-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
96 Tapadar S, He R, Luchini DN, Billadeau DD, Kozikowski AP. Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett 2009;19:3023-6. [PMID: 19419863 DOI: 10.1016/j.bmcl.2009.04.058] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
97 Elliott JT, Samkoe KS, Gunn JR, Stewart EE, Gardner TB, Tichauer KM, Lee TY, Hoopes PJ, Pereira SP, Hasan T, Pogue BW. Perfusion CT estimates photosensitizer uptake and biodistribution in a rabbit orthotopic pancreatic cancer model: a pilot study. Acad Radiol 2015;22:572-9. [PMID: 25683500 DOI: 10.1016/j.acra.2014.12.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
98 Liang C, Yu XJ, Guo XZ, Sun MH, Wang Z, Song Y, Ni QX, Li HY, Mukaida N, Li YY. MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Oncotarget 2015;6:14440-55. [PMID: 25971209 DOI: 10.18632/oncotarget.3885] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
99 Mohammed A, Janakiram NB, Li Q, Madka V, Ely M, Lightfoot S, Crawford H, Steele VE, Rao CV. The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. Cancer Prev Res (Phila). 2010;3:1417-1426. [PMID: 21084261 DOI: 10.1158/1940-6207.capr-10-0038] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
100 Wang Y, Schrag D, Brooks GA, Dominici F. National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010. Cancer 2014;120:1050-8. [PMID: 24382787 DOI: 10.1002/cncr.28537] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
101 Yin T, Shi P, Gou S, Shen Q, Wang C. Dendritic cells loaded with pancreatic Cancer Stem Cells (CSCs) lysates induce antitumor immune killing effect in vitro. PLoS One. 2014;9:e114581. [PMID: 25521461 DOI: 10.1371/journal.pone.0114581] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
102 Baghbanian M, Salmanroghani H, Baghbanian A, Bakhtpour M, Shabazkhani B. Efficacy of multi-detector computerized tomography scan, endoscopic ultrasound, and laparoscopy for predicting tumor resectability in pancreatic adenocarcinoma. Indian J Gastroenterol. 2013;32:376-380. [PMID: 23982702 DOI: 10.1007/s12664-013-0353-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
103 Fu J, Rodova M, Roy SK, Sharma J, Singh KP, Srivastava RK, Shankar S. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. 2013;330:22-32. [PMID: 23200667 DOI: 10.1016/j.canlet.2012.11.018] [Cited by in Crossref: 99] [Cited by in F6Publishing: 100] [Article Influence: 11.0] [Reference Citation Analysis]
104 Trna J, Dítĕ P, Adamcová A, Crawford BJ, Hermanová M. Diabetes mellitus in pancreatic cancer patients in the Czech Republic: sex differences. Exp Diabetes Res 2012;2012:414893. [PMID: 22792091 DOI: 10.1155/2012/414893] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
105 Koay EJ, Baio FE, Ondari A, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Zhang J, Court L, Bhosale PR, Tamm EP, Qayyum A, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Maitra A, Ferrari M, Varadhachary GR, Fleming JB. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol 2014;11:065002. [PMID: 25427073 DOI: 10.1088/1478-3975/11/6/065002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
106 Li D, Ma Y, Liu W, Ren X, Chen M, Xu X, Sheng Z, Zhang K, Zhou R, Goodin S, Zheng X. Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures. Int J Med Sci 2020;17:1795-802. [PMID: 32714082 DOI: 10.7150/ijms.47546] [Reference Citation Analysis]
107 Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM. Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 2008;14:7192-8. [PMID: 19084933 DOI: 10.3748/wjg.14.7192] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 82] [Article Influence: 8.2] [Reference Citation Analysis]
108 Wason MS, Lu H, Yu L, Lahiri SK, Mukherjee D, Shen C, Das S, Seal S, Zhao J. Cerium Oxide Nanoparticles Sensitize Pancreatic Cancer to Radiation Therapy through Oxidative Activation of the JNK Apoptotic Pathway. Cancers (Basel) 2018;10:E303. [PMID: 30200491 DOI: 10.3390/cancers10090303] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
109 He K, Xun P, Brasky TM, Gammon MD, Stevens J, White E. Types of fish consumed and fish preparation methods in relation to pancreatic cancer incidence: the VITAL Cohort Study. Am J Epidemiol. 2013;177:152-160. [PMID: 23221729 DOI: 10.1093/aje/kws232] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
110 Zhao J, Shen H, Hu HG, Huang JJ. Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report. World J Gastroenterol 2015;21:3441-6. [PMID: 25805958 DOI: 10.3748/wjg.v21.i11.3441] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Wang F, Kumar P. The role of radiotherapy in management of pancreatic cancer. J Gastrointest Oncol. 2011;2:157-167. [PMID: 22811846 DOI: 10.3978/j.issn.2078-6891.2011.032] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
112 Zhang JG, Hong DF, Zhang CW, Sun XD, Wang ZF, Shi Y, Liu JW, Shen GL, Zhang YB, Cheng J, Wang CY, Zhao G. Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress. Cancer Sci 2014;105:445-54. [PMID: 24484175 DOI: 10.1111/cas.12364] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
113 Zhang T, Li Y, Zhu Z, Gu M, Newman B, Sun D. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells. Mol Pharm 2010;7:1576-84. [PMID: 20669973 DOI: 10.1021/mp900321a] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
114 Shindo T, Fukukura Y, Umanodan T, Takumi K, Hakamada H, Nakajo M, Umanodan A, Ideue J, Kamimura K, Yoshiura T. Histogram Analysis of Apparent Diffusion Coefficient in Differentiating Pancreatic Adenocarcinoma and Neuroendocrine Tumor. Medicine (Baltimore) 2016;95:e2574. [PMID: 26825900 DOI: 10.1097/MD.0000000000002574] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 5.4] [Reference Citation Analysis]
115 Yao J, Zhang M, Ma QY, Wang Z, Wang LC, Zhang D. PAd-shRNA-PTN reduces pleiotrophin of pancreatic cancer cells and inhibits neurite outgrowth of DRG. World J Gastroenterol. 2011;17:2667-2673. [PMID: 21677838 DOI: 10.3748/wjg.v17.i21.2667] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
116 Xu Y, Du J, Wang Y, Gong B, Wang Y, Qian L, Tan Y. A Highly Responsive Pancreatic Ductal Adenocarcinoma with Liver Metastasis: A Rare Case Report. Int J Gen Med 2021;14:487-96. [PMID: 33623421 DOI: 10.2147/IJGM.S293806] [Reference Citation Analysis]
117 Hagmann W, Jesnowski R, Löhr JM. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 2010;12:740-7. [PMID: 20824050 DOI: 10.1593/neo.10576] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
118 Antwi SO, Fagan SE, Chaffee KG, Bamlet WR, Hu C, Polley EC, Hart SN, Shimelis H, Lilyquist J, Gnanaolivu RD, McWilliams RR, Oberg AL, Couch FJ, Petersen GM. Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status. J Natl Cancer Inst 2019;111:264-71. [PMID: 29982661 DOI: 10.1093/jnci/djx272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
119 Kadhim LA, Dholakia AS, Herman JM, Wahl RL, Chaudhry MA. The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma. J Radiat Oncol 2013;2:341-52. [PMID: 29423019 DOI: 10.1007/s13566-013-0130-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
120 Wei Y, Wang G, Wang C, Zhou Y, Zhang J, Xu K. Upregulation of DUSP14 Affects Proliferation, Invasion and Metastasis, Potentially via Epithelial-Mesenchymal Transition and Is Associated with Poor Prognosis in Pancreatic Cancer. Cancer Manag Res 2020;12:2097-108. [PMID: 32256117 DOI: 10.2147/CMAR.S240040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
121 Guo S, Xu J, Xue R, Liu Y, Yu H. Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis. Int J Clin Oncol 2014;19:319-24. [PMID: 23542947 DOI: 10.1007/s10147-013-0549-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
122 Kang CM, Yun B, Kim M, Song M, Kim YH, Lee SH, Lee H, Lee SM, Lee SM. Postoperative serum metabolites of patients on a low carbohydrate ketogenic diet after pancreatectomy for pancreatobiliary cancer: a nontargeted metabolomics pilot study. Sci Rep 2019;9:16820. [PMID: 31727967 DOI: 10.1038/s41598-019-53287-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
123 Vorvis C, Hatziapostolou M, Mahurkar-Joshi S, Koutsioumpa M, Williams J, Donahue TR, Poultsides GA, Eibl G, Iliopoulos D. Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2016;310:G1124-37. [PMID: 27151939 DOI: 10.1152/ajpgi.00035.2016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
124 Godfrey JD, Morton JP, Wilczynska A, Sansom OJ, Bushell MD. MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus. Cell Death Dis 2018;9:644. [PMID: 29844410 DOI: 10.1038/s41419-018-0628-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
125 Rahbari NN, Bork U, Hinz U, Leo A, Kirchberg J, Koch M, Büchler MW, Weitz J. AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer 2012;12:319. [PMID: 22838843 DOI: 10.1186/1471-2407-12-319] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
126 Opfermann KJ, Wahlquist AE, Garrett-Mayer E, Shridhar R, Cannick L, Marshall DT. Adjuvant radiotherapy and lymph node status for pancreatic cancer: results of a study from the Surveillance, Epidemiology, and End Results (SEER) Registry Data. Am J Clin Oncol 2014;37:112-6. [PMID: 23211221 DOI: 10.1097/COC.0b013e31826e0570] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
127 Chen J, Domingue JC, Sears CL. Microbiota dysbiosis in select human cancers: Evidence of association and causality. Semin Immunol 2017;32:25-34. [PMID: 28822617 DOI: 10.1016/j.smim.2017.08.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 18.5] [Reference Citation Analysis]
128 Haque I, Mehta S, Majumder M, Dhar K, De A, McGregor D, Van Veldhuizen PJ, Banerjee SK, Banerjee S. Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis. Mol Cancer. 2011;10:8. [PMID: 21232118 DOI: 10.1186/1476-4598-10-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 7.2] [Reference Citation Analysis]
129 Bao Q, Zhao Y, Renner A, Niess H, Seeliger H, Jauch KW, Bruns CJ. Cancer stem cells in pancreatic cancer. Cancers (Basel) 2010;2:1629-41. [PMID: 24281178 DOI: 10.3390/cancers2031629] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
130 Sun W, Chen Y, Yuan W. Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors. Int J Nanomedicine 2013;8:1499-506. [PMID: 23626465 DOI: 10.2147/IJN.S41462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
131 Tomihara H, Eguchi H, Yamada D, Gotoh K, Kawamoto K, Wada H, Asaoka T, Noda T, Takeda Y, Tanemura M, Mori M, Doki Y. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Surg Today 2017;47:218-26. [PMID: 27586014 DOI: 10.1007/s00595-016-1405-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
132 Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD. Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev 2014;257:145-64. [PMID: 24329795 DOI: 10.1111/imr.12141] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
133 Lewis S, Sastri SC, Arya S, Mehta S, Patil P, Shrivastava S, Phurailatpam R, Shrikhande SV, Engineer R. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study. J Gastrointest Oncol 2019;10:474-82. [PMID: 31183197 DOI: 10.21037/jgo.2019.01.25] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
134 Lindberg JM, Newhook TE, Adair SJ, Walters DM, Kim AJ, Stelow EB, Parsons JT, Bauer TW. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. Neoplasia. 2014;16:562-571. [PMID: 25117978 DOI: 10.1016/j.neo.2014.06.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
135 Lucien F, Lac V, Billadeau DD, Borgida A, Gallinger S, Leong HS. Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases. Oncotarget 2019;10:1045-55. [PMID: 30800217 DOI: 10.18632/oncotarget.26620] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
136 Zhi YH, Song MM, Wang PL, Zhang T, Yin ZY. Suppression of matrix metalloproteinase-2 via RNA interference inhibits pancreatic carcinoma cell invasiveness and adhesion. World J Gastroenterol 2009;15:1072-8. [PMID: 19266599 DOI: 10.3748/wjg.15.1072] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
137 Long Y, Sun Q, Wu J, Wang Y, Jiao S. Allogeneic cell-based immunotherapy combined with chemotherapy and targeted therapy in advanced pancreatic cancer with metastases: A case report. Oncol Lett 2014;7:1594-8. [PMID: 24765183 DOI: 10.3892/ol.2014.1908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
138 O’Reilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, Tang LH, LaValle J, Winston C, DeMatteo RP. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014;260:142-148. [PMID: 24901360 DOI: 10.1097/sla.0000000000000251] [Cited by in Crossref: 92] [Cited by in F6Publishing: 38] [Article Influence: 13.1] [Reference Citation Analysis]
139 Tai CJ, Huang MT, Wu CH, Wang CK, Tai CJ, Chang CC, Hsieh CI, Chang YJ, Wu CJ, Kuo LJ, Wei PL, Chen RJ, Chiou HY. Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma. Medicine (Baltimore) 2016;95:e3259. [PMID: 27082562 DOI: 10.1097/MD.0000000000003259] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
140 Zhao LL, Zhang T, Zhuang LW, Yan BZ, Wang RF, Liu BR. Uncovering the pathogenesis and identifying novel targets of pancreatic cancer using bioinformatics approach. Mol Biol Rep 2014;41:4697-704. [PMID: 24728565 DOI: 10.1007/s11033-014-3340-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
141 Aberle MR, Burkhart RA, Tiriac H, Olde Damink SWM, Dejong CHC, Tuveson DA, van Dam RM. Patient-derived organoid models help define personalized management of gastrointestinal cancer. Br J Surg. 2018;105:e48-e60. [PMID: 29341164 DOI: 10.1002/bjs.10726] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 21.0] [Reference Citation Analysis]
142 Lin C, Wu WC, Zhao GC, Wang DS, Lou WH, Jin DY. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2016;95:e4527. [PMID: 27495108 DOI: 10.1097/MD.0000000000004527] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
143 Das SK, Wang JL, Li B, Zhang C, Yang HF. Clinical effectiveness of combined interventional therapy as a salvage modality for unresectable pancreatic carcinoma. Oncol Lett 2019;18:375-85. [PMID: 31289509 DOI: 10.3892/ol.2019.10323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Wang X, Li Y, Tian H, Qi J, Li M, Fu C, Wu F, Wang Y, Cheng D, Zhao W, Zhang C, Wang T, Rao J, Zhang W. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. BMC Cancer. 2014;14:578. [PMID: 25106741 DOI: 10.1186/1471-2407-14-578] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]
145 Wakabayashi H, Nishiyama Y, Otani T, Sano T, Yachida S, Okano K, Izuishi K, Suzuki Y. Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol. 2008;14:64-69. [PMID: 18176963 DOI: 10.3748/wjg.14.64] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
146 Wittel UA, Lubgan D, Ghadimi M, Belyaev O, Uhl W, Bechstein WO, Grützmann R, Hohenberger WM, Schmid A, Jacobasch L, Croner RS, Reinacher-Schick A, Hopt UT, Pirkl A, Oettle H, Fietkau R, Golcher H. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial. BMC Cancer 2019;19:979. [PMID: 31640628 DOI: 10.1186/s12885-019-6148-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
147 Tran TB, Maker VK, Maker AV. Impact of Immunotherapy after Resection of Pancreatic Cancer. J Am Coll Surg 2019;229:19-27.e1. [PMID: 30742911 DOI: 10.1016/j.jamcollsurg.2019.01.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
148 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets. 2012;13:811-828. [PMID: 22458528 DOI: 10.1016/j.pestbp.2011.02.012.investigations] [Reference Citation Analysis]
149 Moon JY, Ediriweera MK, Ryu JY, Kim HY, Cho SK. Catechol enhances chemo‑ and radio‑sensitivity by targeting AMPK/Hippo signaling in pancreatic cancer cells. Oncol Rep 2021;45:1133-41. [PMID: 33650657 DOI: 10.3892/or.2021.7924] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
150 Li C, Yu S, Nakamura F, Yin S, Xu J, Petrolla AA, Singh N, Tartakoff A, Abbott DW, Xin W, Sy MS. Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. J Clin Invest 2009;119:2725-36. [PMID: 19690385 DOI: 10.1172/JCI39542] [Cited by in Crossref: 61] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
151 Hanada K, Hino F, Amano H, Fukuda T, Kuroda Y. Current treatment strategies for pancreatic cancer in the elderly. Drugs Aging 2006;23:403-10. [PMID: 16823993 DOI: 10.2165/00002512-200623050-00004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
152 Archange C, Nowak J, Garcia S, Moutardier V, Calvo EL, Dagorn JC, Iovanna JL. The WSB1 gene is involved in pancreatic cancer progression. PLoS One 2008;3:e2475. [PMID: 18575577 DOI: 10.1371/journal.pone.0002475] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
153 Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in Obesity, Inflammation, and Cancer. Diabetes Metab J 2021;45:285-311. [PMID: 33775061 DOI: 10.4093/dmj.2020.0250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
154 Han Q, Deng M, Lv Y, Dai G. Survival of patients with advanced pancreatic cancer after iodine125 seeds implantation brachytherapy: A meta-analysis. Medicine (Baltimore). 2017;96:e5719. [PMID: 28151849 DOI: 10.1097/md.0000000000005719] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
155 Tekin C, Aberson HL, Waasdorp C, Hooijer GKJ, de Boer OJ, Dijk F, Bijlsma MF, Spek CA. Macrophage-secreted MMP9 induces mesenchymal transition in pancreatic cancer cells via PAR1 activation. Cell Oncol (Dordr) 2020;43:1161-74. [PMID: 32809114 DOI: 10.1007/s13402-020-00549-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
156 Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol. 2011;17:867-897. [PMID: 21412497 DOI: 10.3748/wjg.v17.i7.867] [Cited by in CrossRef: 114] [Cited by in F6Publishing: 100] [Article Influence: 11.4] [Reference Citation Analysis]
157 Caso R, Miller G. Role of tumor associated macrophages in regulating pancreatic cancer progression. WJI 2016;6:9. [DOI: 10.5411/wji.v6.i1.9] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
158 Hugenschmidt H, Labori KJ, Brunborg C, Verbeke CS, Seeberg LT, Bendigtsen Schirmer C, Renolen A, Borgen E, Naume B, Wiedswang G. Cytokeratin-positive cells in the bone marrow from patients with pancreatic, periampullary malignancy and benign pancreatic disease show no prognostic information. BMC Cancer 2020;20:1107. [PMID: 33198661 DOI: 10.1186/s12885-020-07510-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Chang JS, Chen LT, Shan YS, Chu PY, Tsai CR, Tsai HJ. The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nation-wide cancer registry-based study from Taiwan. Cancer Med 2018;7:5775-88. [PMID: 30264519 DOI: 10.1002/cam4.1795] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
160 Zhang Y, Zhang R, Luo G, Ai K. Long noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT signaling pathway in pancreatic ductal adenocarcinoma. J Cancer 2018;9:2713-22. [PMID: 30087712 DOI: 10.7150/jca.26207] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
161 Yan Q, Hu D, Li M, Chen Y, Wu X, Ye Q, Wang Z, He L, Zhu J. The Serum MicroRNA Signatures for Pancreatic Cancer Detection and Operability Evaluation. Front Bioeng Biotechnol. 2020;8:379. [PMID: 32411694 DOI: 10.3389/fbioe.2020.00379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
162 Polireddy K, Dong R, McDonald PR, Wang T, Luke B, Chen P, Broward M, Roy A, Chen Q. Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation. PLoS One 2016;11:e0164811. [PMID: 27764163 DOI: 10.1371/journal.pone.0164811] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
163 Rwigema JC, Heron DE, Parikh SD, Zeh HJ, Moser JA, Bahary N, Ashby K, Burton SA. Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins. J Gastrointest Cancer. 2012;43:70-76. [PMID: 20809393 DOI: 10.1007/s12029-010-9203-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
164 Battini S, Faitot F, Imperiale A, Cicek AE, Heimburger C, Averous G, Bachellier P, Namer IJ. Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients. BMC Med. 2017;15:56. [PMID: 28298227 DOI: 10.1186/s12916-017-0810-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
165 Cheng J, Cashman JR. Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression. Invest New Drugs 2021;39:131-41. [PMID: 32915418 DOI: 10.1007/s10637-020-00998-z] [Reference Citation Analysis]
166 Nuccitelli R, Huynh J, Lui K, Wood R, Kreis M, Athos B, Nuccitelli P. Nanoelectroablation of human pancreatic carcinoma in a murine xenograft model without recurrence. Int J Cancer 2013;132:1933-9. [PMID: 23001643 DOI: 10.1002/ijc.27860] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
167 Gagliano N, Celesti G, Tacchini L, Pluchino S, Sforza C, Rasile M, Valerio V, Laghi L, Conte V, Procacci P. Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma: Characterization in a 3D-cell culture model. World J Gastroenterol 2016;22:4466-83. [PMID: 27182158 DOI: 10.3748/wjg.v22.i18.4466] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
168 Chen RY, Xu B, Chen SF, Chen SS, Zhang T, Ren J, Xu J. Effect of oridonin-mediated hallmark changes on inflammatory pathways in human pancreatic cancer (BxPC-3) cells. World J Gastroenterol 2014;20:14895-903. [PMID: 25356049 DOI: 10.3748/wjg.v20.i40.14895] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
169 Piperdi M, McDade TP, Shim JK, Piperdi B, Kadish SP, Sullivan ME, Whalen GF, Tseng JF. A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database. HPB (Oxford) 2010;12:204-10. [PMID: 20590888 DOI: 10.1111/j.1477-2574.2009.00150.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
170 Foley K, Rucki AA, Xiao Q, Zhou D, Leubner A, Mo G, Kleponis J, Wu AA, Sharma R, Jiang Q, Anders RA, Iacobuzio-Donahue CA, Hajjar KA, Maitra A, Jaffee EM, Zheng L. Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Sci Signal 2015;8:ra77. [PMID: 26243191 DOI: 10.1126/scisignal.aaa5823] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 8.5] [Reference Citation Analysis]
171 Barreto SG, Shukla PJ, Shrikhande SV. Tumors of the Pancreatic Body and Tail. World J Oncol. 2010;1:52-65. [PMID: 29147182 DOI: 10.4021/wjon2010.04.200w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
172 Thakur PC, Miller-Ocuin JL, Nguyen K, Matsuda R, Singhi AD, Zeh HJ, Bahary N. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. J Transl Med 2018;16:190. [PMID: 29986726 DOI: 10.1186/s12967-018-1562-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
173 Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res 2008;14:6744-50. [PMID: 18980967 DOI: 10.1158/1078-0432.CCR-08-1032] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
174 Fry LC, Mönkemüller K, Malfertheiner P. Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg. 2008;393:883-890. [PMID: 18266003 DOI: 10.1007/s00423-007-0276-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
175 Zhai H, Zhang X, Sun X, Zhang D, Ma S. Long Non-coding RNA LINC01420 Contributes to Pancreatic Cancer Progression Through Targeting KRAS Proto-oncogene. Dig Dis Sci 2020;65:1042-52. [PMID: 31562613 DOI: 10.1007/s10620-019-05829-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
176 Miao F, Zhu J, Chen Y, Tang N, Wang X, Li X. MicroRNA-183-5p promotes the proliferation, invasion and metastasis of human pancreatic adenocarcinoma cells. Oncol Lett 2016;11:134-40. [PMID: 26870180 DOI: 10.3892/ol.2015.3872] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
177 Li Y, Tang CG, Zhao Y, Cao WY, Qu GF. Outcomes and prognostic factors of patients with stage IB and IIA pancreatic cancer according to the 8th edition American Joint Committee on Cancer criteria. World J Gastroenterol 2017;23:2757-62. [PMID: 28487613 DOI: 10.3748/wjg.v23.i15.2757] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
178 Kitajima K, Murakami K, Yamasaki E, Kaji Y, Shimoda M, Kubota K, Suganuma N, Sugimura K. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Mol Imaging Biol. 2010;12:452-459. [PMID: 19949988 DOI: 10.1007/s11307-009-0271-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
179 Bye A, Wesseltoft-Rao N, Iversen PO, Skjegstad G, Holven KB, Ulven S, Hjermstad MJ. Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer. Med Oncol 2016;33:54. [PMID: 27119533 DOI: 10.1007/s12032-016-0768-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
180 Jeong SM, Hwang S, Park K, Yang S, Seong RH. Enhanced mitochondrial glutamine anaplerosis suppresses pancreatic cancer growth through autophagy inhibition. Sci Rep 2016;6:30767. [PMID: 27477484 DOI: 10.1038/srep30767] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
181 Strell C, Norberg KJ, Mezheyeuski A, Schnittert J, Kuninty PR, Moro CF, Paulsson J, Schultz NA, Calatayud D, Löhr JM, Frings O, Verbeke CS, Heuchel RL, Prakash J, Johansen JS, Östman A. Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC. Br J Cancer 2017;117:65-77. [PMID: 28524160 DOI: 10.1038/bjc.2017.140] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
182 Lee J, Lee J, Yun JH, Choi C, Cho S, Kim SJ, Kim JH. Autocrine DUSP28 signaling mediates pancreatic cancer malignancy via regulation of PDGF-A. Sci Rep 2017;7:12760. [PMID: 28986588 DOI: 10.1038/s41598-017-13023-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
183 Wu K, Hu G, He X, Zhou P, Li J, He B, Sun W. MicroRNA-424-5p suppresses the expression of SOCS6 in pancreatic cancer. Pathol Oncol Res 2013;19:739-48. [PMID: 23653113 DOI: 10.1007/s12253-013-9637-x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 7.8] [Reference Citation Analysis]
184 Collins AL, Rock J, Malhotra L, Frankel WL, Bloomston M. Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma. Ann Surg Oncol 2012;19:2673-8. [PMID: 22461132 DOI: 10.1245/s10434-012-2337-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
185 Belli C, Cereda S, Reni M. Role of taxanes in pancreatic cancer. World J Gastroenterol 2012;18:4457-65. [PMID: 22969215 DOI: 10.3748/wjg.v18.i33.4457] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
186 Yu YP, Yu Q, Guo JM, Jiang HT, Di XY, Zhu Y. Effectiveness and security of CT-guided percutaneous implantation of (125)I seeds in pancreatic carcinoma. Br J Radiol. 2014;87:20130642. [PMID: 24734936 DOI: 10.1259/bjr.20130642] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
187 Park Y, Jun HR, Choi HW, Hwang DW, Lee JH, Song KB, Lee W, Kwon J, Ha SH, Jun E, Kim SC. Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma. Sci Rep 2021;11:1644. [PMID: 33462311 DOI: 10.1038/s41598-020-80383-1] [Reference Citation Analysis]
188 Majumder S, Bockorny B, Baker WL, Dasanu CA. Association between HBsAg positivity and pancreatic cancer: a meta-analysis. J Gastrointest Cancer 2014;45:347-52. [PMID: 24788082 DOI: 10.1007/s12029-014-9618-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
189 Wang N, Gaddam S, Wang L, Xie Y, Fan Z, Yang W, Tuli R, Lo S, Hendifar A, Pandol S, Christodoulou AG, Li D. Six-dimensional quantitative DCE MR Multitasking of the entire abdomen: Method and application to pancreatic ductal adenocarcinoma. Magn Reson Med 2020;84:928-48. [PMID: 31961967 DOI: 10.1002/mrm.28167] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
190 Aier I, Semwal R, Dhara A, Sen N, Varadwaj PK. An integrated epigenome and transcriptome analysis identifies PAX2 as a master regulator of drug resistance in high grade pancreatic ductal adenocarcinoma. PLoS One 2019;14:e0223554. [PMID: 31622355 DOI: 10.1371/journal.pone.0223554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
191 Lenggenhager D, Bengs S, Fritsch R, Hussung S, Busenhart P, Endhardt K, Töpfer A, The FO, Bütikofer S, Gubler C, Scharl M, Morell B. β6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma. Clin Transl Gastroenterol 2021;12:e00395. [PMID: 34388137 DOI: 10.14309/ctg.0000000000000395] [Reference Citation Analysis]
192 Kuo KK, Kuo CJ, Chiu CY, Liang SS, Huang CH, Chi SW, Tsai KB, Chen CY, Hsi E, Cheng KH, Chiou SH. Quantitative Proteomic Analysis of Differentially Expressed Protein Profiles Involved in Pancreatic Ductal Adenocarcinoma. Pancreas 2016;45:71-83. [PMID: 26262590 DOI: 10.1097/MPA.0000000000000388] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
193 Yu YP, Yu Q, Guo JM, Jiang HT, Di XY, Zhu Y. (125)I particle implantation combined with chemoradiotherapy to treat advanced pancreatic cancer. Br J Radiol 2014;87:20130641. [PMID: 24625042 DOI: 10.1259/bjr.20130641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
194 Lachowski D, Cortes E, Pink D, Chronopoulos A, Karim SA, P Morton J, Del Río Hernández AE. Substrate Rigidity Controls Activation and Durotaxis in Pancreatic Stellate Cells. Sci Rep 2017;7:2506. [PMID: 28566691 DOI: 10.1038/s41598-017-02689-x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 14.8] [Reference Citation Analysis]
195 Reilley MJ, Shroff R, Varadhachary GR. Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer. Indian J Surg 2015;77:403-8. [PMID: 26722204 DOI: 10.1007/s12262-015-1361-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
196 Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 25.0] [Reference Citation Analysis]
197 Chang JC, Kundranda M. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. Int J Mol Sci. 2017;18. [PMID: 28335509 DOI: 10.3390/ijms18030667] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 13.5] [Reference Citation Analysis]
198 Jin T, Dai C, Xu F. Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: recent advances and future prospects. Ther Adv Med Oncol 2020;12:1758835920933034. [PMID: 32636941 DOI: 10.1177/1758835920933034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
199 O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol 2015;26:1923-9. [PMID: 26091808 DOI: 10.1093/annonc/mdv264] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
200 Li B, Wan X, Zhu Q, Li L, Zeng Y, Hu D, Qian Y, Lu L, Wang X, Meng X. Net expression inhibits the growth of pancreatic ductal adenocarcinoma cell PL45 in vitro and in vivo. PLoS One 2013;8:e57818. [PMID: 23469073 DOI: 10.1371/journal.pone.0057818] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
201 Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 2011;10:3-8. [PMID: 21135251 DOI: 10.1158/1535-7163.mct-10-0893] [Cited by in Crossref: 193] [Cited by in F6Publishing: 113] [Article Influence: 17.5] [Reference Citation Analysis]
202 Li W, Wang Y, Kellner DB, Xu L, Mai L. Efficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinoma. Cent Eur J Immunol 2015;40:188-93. [PMID: 26557033 DOI: 10.5114/ceji.2015.52833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
203 Wieder H, Beer AJ, Siveke J, Schuster T, Buck AK, Herrmann K, Stollfuss JC. 18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer. Oncotarget 2018;9:10128-34. [PMID: 29515797 DOI: 10.18632/oncotarget.24176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
204 Wakatsuki T, Irisawa A, Terashima M, Shibukawa G, Takagi T, Imamura H, Takahashi Y, Sato A, Sato M, Ikeda T, Suzuki R, Hikichi T, Obara K, Ohira H. ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration. Int J Clin Oncol 2011;16:387-94. [PMID: 21331767 DOI: 10.1007/s10147-011-0197-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
205 Cheng HB, Bo Y, Shen WX, Ren XG, Tan JN, Jia ZR, Xu CL. Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn Schmiedebergs Arch Pharmacol 2015;388:623-34. [PMID: 25743573 DOI: 10.1007/s00210-015-1107-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
206 Hao JG, Wang JP, Gu YL, Lu ML. Importance of b value in diffusion weighted imaging for the diagnosis of pancreatic cancer. World J Gastroenterol. 2013;19:6651-6655. [PMID: 24151395 DOI: 10.3748/wjg.v19.i39.6651] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
207 Zhong J, Switchenko J, Behera M, Kooby D, Maithel SK, McDonald MW, Lin JY, Cassidy RJ, El-Rayes B, Landry J, Patel PR. Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. Ann Surg Oncol 2018;25:1026-33. [PMID: 29327180 DOI: 10.1245/s10434-017-6322-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
208 Motoo Y, Shimasaki T, Ishigaki Y, Nakajima H, Kawakami K, Minamoto T. Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: implications for new therapeutic strategies. Cancers (Basel) 2011;3:446-60. [PMID: 24212624 DOI: 10.3390/cancers3010446] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
209 Xiong J, Wang D, Wei A, Ke N, Wang Y, Tang J, He S, Hu W, Liu X. MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy. Oncotarget 2017;8:107500-12. [PMID: 29296182 DOI: 10.18632/oncotarget.22494] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
210 Gaidhane M, Smith I, Ellen K, Gatesman J, Habib N, Foley P, Moskaluk C, Kahaleh M. Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) of the Pancreas in a Porcine Model. Gastroenterol Res Pract. 2012;2012:431451. [PMID: 23049547 DOI: 10.1155/2012/431451] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
211 Chuong MD, Frakes JM, Figura N, Hoffe SE, Shridhar R, Mellon EA, Hodul PJ, Malafa MP, Springett GM, Centeno BA. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. J Gastrointest Oncol 2016;7:221-7. [PMID: 27034789 DOI: 10.3978/j.issn.2078-6891.2015.075] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
212 Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008;7:829-40. [PMID: 18413796 DOI: 10.1158/1535-7163.MCT-07-0337] [Cited by in Crossref: 214] [Cited by in F6Publishing: 131] [Article Influence: 16.5] [Reference Citation Analysis]
213 Choi HJ, Kang CM, Lee WJ, Song SY, Cho A, Yun M, Lee JD, Kim JH, Lee JH. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer. Yonsei Med J. 2013;54:1377-1383. [PMID: 24142641 DOI: 10.3349/ymj.2013.54.6.1377] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
214 Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, García-García E, López-Ríos F, Matsui W. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther. 2009;8:310-314. [PMID: 19174553 DOI: 10.1158/1535-7163.mct-08-924] [Reference Citation Analysis]
215 Valkovskaya N, Kayed H, Felix K, Hartmann D, Giese NA, Osinsky SP, Friess H, Kleeff J. ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J Cell Mol Med 2007;11:1162-74. [PMID: 17979891 DOI: 10.1111/j.1582-4934.2007.00082.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.0] [Reference Citation Analysis]
216 Simon PO Jr, McDunn JE, Kashiwagi H, Chang K, Goedegebuure PS, Hotchkiss RS, Hawkins WG. Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Int J Cancer 2009;125:942-51. [PMID: 19405118 DOI: 10.1002/ijc.24424] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
217 McDowell BD, Chapman CG, Smith BJ, Button AM, Chrischilles EA, Mezhir JJ. Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: results of an instrumental variable analysis. Ann Surg. 2015;261:740-745. [PMID: 24979599 DOI: 10.1097/sla.0000000000000796] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
218 Leppänen J, Helminen O, Huhta H, Kauppila JH, Isohookana J, Haapasaari KM, Lehenkari P, Saarnio J, Karttunen TJ. High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients. Virchows Arch 2017;470:401-10. [PMID: 28191612 DOI: 10.1007/s00428-017-2087-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
219 Li S, Sun J, Yang J, Zhang L, Wang L, Wang X, Guo Z. XIAP expression is associated with pancreatic carcinoma outcome. Mol Clin Oncol 2013;1:305-8. [PMID: 24649165 DOI: 10.3892/mco.2013.58] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
220 Andersson G, Borgquist S, Jirström K. Hormonal factors and pancreatic cancer risk in women: The Malmö Diet and Cancer Study. Int J Cancer 2018;143:52-62. [PMID: 29424426 DOI: 10.1002/ijc.31302] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
221 Jono H, Ando Y. Midkine: a novel prognostic biomarker for cancer. Cancers (Basel) 2010;2:624-41. [PMID: 24281085 DOI: 10.3390/cancers2020624] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
222 Lee Y, Koay EJ, Zhang W, Qin L, Kirui DK, Hussain F, Shen H, Ferrari M. Human equilibrative nucleoside transporter-1 knockdown tunes cellular mechanics through epithelial-mesenchymal transition in pancreatic cancer cells. PLoS One. 2014;9:e107973. [PMID: 25314577 DOI: 10.1371/journal.pone.0107973] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
223 Rahman F, Cotterchio M, Cleary SP, Gallinger S. Association between alcohol consumption and pancreatic cancer risk: a case-control study. PLoS One. 2015;10:e0124489. [PMID: 25856529 DOI: 10.1371/journal.pone.0124489] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
224 Lu YY, Jing DD, Xu M, Wu K, Wang XP. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World J Gastroenterol. 2008;14:5403-5411. [PMID: 18803351 DOI: 10.3748/wjg.14.5403] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
225 Humbert M, Castéran N, Letard S, Hanssens K, Iovanna J, Finetti P, Bertucci F, Bader T, Mansfield CD, Moussy A. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS One. 2010;5:e9430. [PMID: 20209107 DOI: 10.1371/journal.pone.0009430] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
226 Tjomsland V, Bojmar L, Sandström P, Bratthäll C, Messmer D, Spångeus A, Larsson M. IL-1α expression in pancreatic ductal adenocarcinoma affects the tumor cell migration and is regulated by the p38MAPK signaling pathway. PLoS One 2013;8:e70874. [PMID: 23951028 DOI: 10.1371/journal.pone.0070874] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
227 Li Y, Xi Z, Chen X, Cai S, Liang C, Wang Z, Li Y, Tan H, Lao Y, Xu H. Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways. Cell Death Dis 2018;9:538. [PMID: 29749405 DOI: 10.1038/s41419-018-0574-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
228 Fulda S. Targeting apoptosis signaling in pancreatic cancer. Cancers (Basel). 2011;3:241-251. [PMID: 24212616 DOI: 10.3390/cancers3010241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
229 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33. [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
230 Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D, Akin D, Paster BJ, Joshipura K, Wong DT. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut. 2012;61:582-588. [PMID: 21994333 DOI: 10.1136/gutjnl-2011-300784] [Cited by in Crossref: 306] [Cited by in F6Publishing: 267] [Article Influence: 30.6] [Reference Citation Analysis]
231 Hang J, Xue P, Yang H, Li S, Chen D, Zhu L, Huang W, Ren S, Zhu Y, Wang L. Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Sci Rep 2017;7:2993. [PMID: 28592881 DOI: 10.1038/s41598-017-03153-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
232 Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2018;9:7204-18. [PMID: 29467962 DOI: 10.18632/oncotarget.23208] [Cited by in Crossref: 821] [Cited by in F6Publishing: 621] [Article Influence: 205.3] [Reference Citation Analysis]
233 Seaman ME, Contino G, Bardeesy N, Kelly KA. Molecular imaging agents: impact on diagnosis and therapeutics in oncology. Expert Rev Mol Med. 2010;12:e20. [PMID: 20633310 DOI: 10.1017/s1462399410001511] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
234 Cao Z, Xu J, Huang H, Shen P, You L, Zhou L, Zheng L, Zhang T, Zhao Y. MiR-1178 promotes the proliferation, G1/S transition, migration and invasion of pancreatic cancer cells by targeting CHIP. PLoS One 2015;10:e0116934. [PMID: 25635996 DOI: 10.1371/journal.pone.0116934] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
235 Osterman M, Kathawa D, Liu D, Guo H, Zhang C, Li M, Yu X, Li F. Elevated DNA damage response in pancreatic cancer. Histochem Cell Biol. 2014;142:713-720. [PMID: 25002126 DOI: 10.1007/s00418-014-1245-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
236 Samuel N, Hudson TJ. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;9:77-87. [PMID: 22183185 DOI: 10.1038/nrgastro.2011.215] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 5.7] [Reference Citation Analysis]
237 Zhang B, Song L, Cai J, Li L, Xu H, Li M, Wang J, Shi M, Chen H, Jia H, Hou Z. The LIM protein Ajuba/SP1 complex forms a feed forward loop to induce SP1 target genes and promote pancreatic cancer cell proliferation. J Exp Clin Cancer Res 2019;38:205. [PMID: 31101117 DOI: 10.1186/s13046-019-1203-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
238 Wang W, Zhan L, Guo D, Xiang Y, Zhang Y, Tian M, Han Z. Transcriptome analysis of pancreatic cancer cell response to treatment with grape seed proanthocyanidins. Oncol Lett 2019;17:1741-9. [PMID: 30675233 DOI: 10.3892/ol.2018.9807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
239 Hayashi H, Higashi T, Miyata T, Yamashita YI, Baba H. Recent advances in precision medicine for pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:457-66. [PMID: 34337294 DOI: 10.1002/ags3.12436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA; NCCN Pancreatic Adenocarcinoma. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010;8:972-1017. [PMID: 20876541 DOI: 10.6004/jnccn.2010.0073] [Cited by in Crossref: 122] [Cited by in F6Publishing: 107] [Article Influence: 11.1] [Reference Citation Analysis]
241 Xie C, Xu X, Wang X, Wei S, Shao L, Chen J, Cai J, Jia L. Cyclooxygenase-2 induces angiogenesis in pancreatic cancer mediated by prostaglandin E2. Oncol Lett. 2018;16:940-948. [PMID: 29963167 DOI: 10.3892/ol.2018.8786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
242 Funamizu N, Lacy CR, Fujita K, Furukawa K, Misawa T, Yanaga K, Manome Y. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One 2012;7:e37424. [PMID: 22616006 DOI: 10.1371/journal.pone.0037424] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
243 Meduri B, Gregucci F, D'Angelo E, Alitto AR, Ciurlia E, Desideri I, Marino L, Borghetti P, Fiore M, Fiorentino A; AIRO Giovani -Italian Association of Radiation Oncology-Young Members. Volume de-escalation in radiation therapy: state of the art and new perspectives. J Cancer Res Clin Oncol 2020;146:909-24. [PMID: 32072318 DOI: 10.1007/s00432-020-03152-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
244 Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, Raoul JL, Bachellier P, Dufour P, Moehler M, Weber A, Lang H, Rogiers X, Clavien PA. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer. 2011;11:346. [PMID: 21831266 DOI: 10.1186/1471-2407-11-346] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 7.1] [Reference Citation Analysis]
245 Yokoi K, Kim SJ, Thaker P, Yazici S, Nam DH, He J, Sasaki T, Chiao PJ, Sclabas GM, Abbruzzese JL, Hamilton SR, Fidler IJ. Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. Neoplasia 2005;7:696-704. [PMID: 16026649 DOI: 10.1593/neo.05193] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
246 Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C, Wang Y, Xue J, Qi W, Sun Q, Zhang S, Hu J, Xu H. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol 2018;11:102. [PMID: 30103775 DOI: 10.1186/s13045-018-0646-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
247 Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, Sho M, Tsuchida A, Unno M; Study Group of Preoperative therapy for Pancreatic cancer (PREP). A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol 2019;54:194-203. [PMID: 30182219 DOI: 10.1007/s00535-018-1506-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
248 Procacci P, Moscheni C, Sartori P, Sommariva M, Gagliano N. Tumor⁻Stroma Cross-Talk in Human Pancreatic Ductal Adenocarcinoma: A Focus on the Effect of the Extracellular Matrix on Tumor Cell Phenotype and Invasive Potential. Cells 2018;7:E158. [PMID: 30301152 DOI: 10.3390/cells7100158] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
249 Huang C, Yang G, Jiang T, Cao J, Huang KJ, Qiu ZJ. Down-regulation of STAT3 expression by vector-based small interfering RNA inhibits pancreatic cancer growth. World J Gastroenterol 2011;17:2992-3001. [PMID: 21799645 DOI: 10.3748/wjg.v17.i25.2992] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
250 Xu YP, Yang M. Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals. World J Gastrointest Oncol 2016;8:165-72. [PMID: 26909131 DOI: 10.4251/wjgo.v8.i2.165] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
251 Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol. 2014;20:7864-7877. [PMID: 24976723 DOI: 10.3748/wjg.v20.i247864] [Reference Citation Analysis]
252 Luo D, Carter KA, Molins EAG, Straubinger NL, Geng J, Shao S, Jusko WJ, Straubinger RM, Lovell JF. Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals. J Control Release 2019;297:39-47. [PMID: 30684512 DOI: 10.1016/j.jconrel.2019.01.030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
253 Tachezy M, Zander H, Marx AH, Stahl PR, Gebauer F, Izbicki JR, Bockhorn M. ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One 2012;7:e39018. [PMID: 22745698 DOI: 10.1371/journal.pone.0039018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
254 Ferreira CA, Ehlerding EB, Rosenkrans ZT, Jiang D, Sun T, Aluicio-Sarduy E, Engle JW, Ni D, Cai W. 86/90Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics. Mol Pharm 2020;17:1697-705. [PMID: 32202792 DOI: 10.1021/acs.molpharmaceut.0c00127] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
255 Feld FM, Nagel PD, Weissinger SE, Welke C, Stenzinger A, Möller P, Lennerz JK. GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma. Oncotarget 2015;6:4516-26. [PMID: 25595905 DOI: 10.18632/oncotarget.2799] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
256 Okamoto K, Ocker M, Neureiter D, Dietze O, Zopf S, Hahn EG, Herold C. bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med 2007;11:349-61. [PMID: 17378914 DOI: 10.1111/j.1582-4934.2007.00013.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
257 Katiyar SK, Athar M. Grape seeds: ripe for cancer chemoprevention. Cancer Prev Res (Phila) 2013;6:617-21. [PMID: 23771521 DOI: 10.1158/1940-6207.CAPR-13-0193] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
258 Lin Z, Simeone DM, Anderson MA, Brand RE, Xie X, Shedden KA, Ruffin MT, Lubman DM. Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer. J Proteome Res 2011;10:2602-11. [PMID: 21417406 DOI: 10.1021/pr200102h] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
259 Harada T, Chelala C, Bhakta V, Chaplin T, Caulee K, Baril P, Young BD, Lemoine NR. Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 2008;27:1951-60. [PMID: 17952125 DOI: 10.1038/sj.onc.1210832] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 6.8] [Reference Citation Analysis]
260 Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, Stommel JM, Dell’antonio G. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011;25:717-729. [PMID: 21406549 DOI: 10.1101/gad.2016111] [Cited by in Crossref: 862] [Cited by in F6Publishing: 779] [Article Influence: 86.2] [Reference Citation Analysis]
261 Li W, Lebrun DG, Li M. The expression and functions of microRNAs in pancreatic adenocarcinoma and hepatocellular carcinoma. Chin J Cancer. 2011;30:540-550. [PMID: 21801602 DOI: 10.5732/cjc.011.10197] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
262 Lener MR, Scott RJ, Wiechowska-Kozłowska A, Serrano-Fernández P, Baszuk P, Jaworska-Bieniek K, Sukiennicki G, Marciniak W, Muszyńska M, Kładny J, Gromowski T, Kaczmarek K, Jakubowska A, Lubiński J. Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer. Cancer Res Treat 2016;48:1056-64. [PMID: 26727715 DOI: 10.4143/crt.2015.282] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
263 Deeb D, Brigolin C, Gao X, Liu Y, Pindolia KR, Gautam SC. Induction of Apoptosis in Pancreatic Cancer Cells by CDDO-Me Involves Repression of Telomerase through Epigenetic Pathways. J Carcinog Mutagen 2014;5:177. [PMID: 25152840 DOI: 10.4172/2157-2518.1000177] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
264 Zubair H, Azim S, Srivastava SK, Ahmad A, Bhardwaj A, Khan MA, Patel GK, Arora S, Carter JE, Singh S, Singh AP. Glucose Metabolism Reprogrammed by Overexpression of IKKε Promotes Pancreatic Tumor Growth. Cancer Res 2016;76:7254-64. [PMID: 27923829 DOI: 10.1158/0008-5472.CAN-16-1666] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
265 Muñoz M, Coveñas R. Targeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic Approach. Cancers (Basel) 2015;7:1215-32. [PMID: 26154566 DOI: 10.3390/cancers7030832] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
266 Roshanravan N, Asgharian P, Dariushnejad H, Mesri Alamdari N, Mansoori B, Mohammadi A, Alipour S, Barati M, Ghavami A, Ghorbanzadeh V, Aamazadeh F, Ostadrahimi A. Eryngium Billardieri Induces Apoptosis via Bax Gene Expression in Pancreatic Cancer Cells. Adv Pharm Bull 2018;8:667-74. [PMID: 30607339 DOI: 10.15171/apb.2018.075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
267 Park JY, Helm J, Coppola D, Kim D, Malafa M, Kim SJ. MicroRNAs in pancreatic ductal adenocarcinoma. World J Gastroenterol. 2011;17:817-827. [PMID: 21412491 DOI: 10.3748/wjg.v17.i7.817] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
268 Tjomsland V, Sandström P, Spångeus A, Messmer D, Emilsson J, Falkmer U, Falkmer S, Magnusson KE, Borch K, Larsson M. Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity? BMC Cancer 2010;10:87. [PMID: 20214814 DOI: 10.1186/1471-2407-10-87] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
269 Li J, Di Y, Jin C, Fu D, Yang F, Jiang Y, Yao L, Hao S, Wang X, Subedi S, Ni Q. Gemcitabine-loaded albumin nanospheres (GEM-ANPs) inhibit PANC-1 cells in vitro and in vivo. Nanoscale Res Lett 2013;8:176. [PMID: 23594566 DOI: 10.1186/1556-276X-8-176] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
270 Ouyang G, Liu Z, Huang S, Li Q, Xiong L, Miao X, Wen Y. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis. World J Surg Oncol 2016;14:59. [PMID: 26927942 DOI: 10.1186/s12957-016-0813-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
271 Jung W, Park T, Kim Y, Park H, Han Y, He J, Wolfgang CL, Blair A, Rashid MF, Kluger MD, Su GH, Chabot JA, Yang CY, Lou W, Valente R, Del Chiaro M, Shyr YM, Wang SE, van Huijgevoort NCM, Besselink MG, Yang Y, Kim H, Kwon W, Kim SW, Jang JY. Validation of a nomogram to predict the risk of cancer in patients with intraductal papillary mucinous neoplasm and main duct dilatation of 10 mm or less. Br J Surg 2019;106:1829-36. [PMID: 31441048 DOI: 10.1002/bjs.11293] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
272 Lu Y, Li C, Chen H, Zhong W. Identification of hub genes and analysis of prognostic values in pancreatic ductal adenocarcinoma by integrated bioinformatics methods. Mol Biol Rep 2018;45:1799-807. [PMID: 30173393 DOI: 10.1007/s11033-018-4325-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
273 Mazza T, Gioffreda D, Fontana A, Biagini T, Carella M, Palumbo O, Maiello E, Bazzocchi F, Andriulli A, Tavano F. Clinical Significance of Circulating miR-1273g-3p and miR-122-5p in Pancreatic Cancer. Front Oncol 2020;10:44. [PMID: 32117716 DOI: 10.3389/fonc.2020.00044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
274 Akcam AT, Teke Z, Saritas AG, Ulku A, Guney IB, Rencuzogullari A. The efficacy of 18F-FDG PET/CT in the preoperative evaluation of pancreatic lesions. Ann Surg Treat Res 2020;98:184-9. [PMID: 32274366 DOI: 10.4174/astr.2020.98.4.184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
275 Huang JS, Egger ME, Grizzle WE, McNally LR. MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells. Biotech Histochem 2013;88:397-402. [PMID: 23373509 DOI: 10.3109/10520295.2012.762460] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
276 Fofaria NM, Srivastava SK. STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells. Carcinogenesis 2015;36:142-50. [PMID: 25411359 DOI: 10.1093/carcin/bgu233] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 9.6] [Reference Citation Analysis]
277 Adwan H, Zhivkova-Galunska M, Georges R, Eyol E, Kleeff J, Giese NA, Friess H, Bergmann F, Berger MR. Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma. Br J Cancer 2011;105:288-95. [PMID: 21712827 DOI: 10.1038/bjc.2011.217] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
278 Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs. 2012;30:1138-1143. [PMID: 21170759 DOI: 10.1007/s10637-010-9619-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
279 Wong J, Solomon NL, Hsueh CT. Neoadjuvant treatment for resectable pancreatic adenocarcinoma. World J Clin Oncol 2016;7:1-8. [PMID: 26862486 DOI: 10.5306/wjco.v7.i1.1] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
280 Wu C, Miao X, Huang L, Che X, Jiang G, Yu D, Yang X, Cao G, Hu Z, Zhou Y, Zuo C, Wang C, Zhang X, Zhou Y, Yu X, Dai W, Li Z, Shen H, Liu L, Chen Y, Zhang S, Wang X, Zhai K, Chang J, Liu Y, Sun M, Cao W, Gao J, Ma Y, Zheng X, Cheung ST, Jia Y, Xu J, Tan W, Zhao P, Wu T, Wang C, Lin D. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat Genet. 2011;44:62-66. [PMID: 22158540 DOI: 10.1038/ng.1020] [Cited by in Crossref: 128] [Cited by in F6Publishing: 108] [Article Influence: 12.8] [Reference Citation Analysis]
281 Eissa MAL, Lerner L, Abdelfatah E, Shankar N, Canner JK, Hasan NM, Yaghoobi V, Huang B, Kerner Z, Takaesu F, Wolfgang C, Kwak R, Ruiz M, Tam M, Pisanic TR 2nd, Iacobuzio-Donahue CA, Hruban RH, He J, Wang TH, Wood LD, Sharma A, Ahuja N. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin Epigenetics. 2019;11:59. [PMID: 30953539 DOI: 10.1186/s13148-019-0650-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 19.0] [Reference Citation Analysis]
282 Chai MG, Kim-Fuchs C, Angst E, Sloan EK. Bioluminescent orthotopic model of pancreatic cancer progression. J Vis Exp 2013. [PMID: 23852391 DOI: 10.3791/50395] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
283 Dovzhanskiy DI, Arnold SM, Hackert T, Oehme I, Witt O, Felix K, Giese N, Werner J. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer. BMC Cancer. 2012;12:226. [PMID: 22681698 DOI: 10.1186/1471-2407-12-226] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
284 Hernandez YG, Lucas AL. MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions. World J Gastrointest Oncol 2016;8:18-29. [PMID: 26798434 DOI: 10.4251/wjgo.v8.i1.18] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
285 Sommariva M, Gagliano N. E-Cadherin in Pancreatic Ductal Adenocarcinoma: A Multifaceted Actor during EMT. Cells 2020;9:E1040. [PMID: 32331358 DOI: 10.3390/cells9041040] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 20.0] [Reference Citation Analysis]
286 Zielinska E, Zauszkiewicz-Pawlak A, Wojcik M, Inkielewicz-Stepniak I. Silver nanoparticles of different sizes induce a mixed type of programmed cell death in human pancreatic ductal adenocarcinoma. Oncotarget 2018;9:4675-97. [PMID: 29435134 DOI: 10.18632/oncotarget.22563] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
287 Marzoq AJ, Giese N, Hoheisel JD, Alhamdani MS. Proteome variations in pancreatic stellate cells upon stimulation with proinflammatory factors. J Biol Chem. 2013;288:32517-32527. [PMID: 24089530 DOI: 10.074/jbc.m] [Reference Citation Analysis]
288 Falasca M, Maffucci T. Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. Front Physiol 2014;5:391. [PMID: 25360116 DOI: 10.3389/fphys.2014.00391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
289 Yao J, Ma Q, Wang L, Zhang M. Pleiotrophin expression in human pancreatic cancer and its correlation with clinicopathological features, perineural invasion, and prognosis. Dig Dis Sci. 2009;54:895-901. [PMID: 18716876 DOI: 10.1007/s10620-008-0433-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
290 Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res. 2008;14:5142-5149. [PMID: 18698032 DOI: 10.1158/1078-0432.ccr-07-4072] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 6.7] [Reference Citation Analysis]
291 Schmahl MJ, Regan DP, Rivers AC, Joesten WC, Kennedy MA. NMR-based metabolic profiling of urine, serum, fecal, and pancreatic tissue samples from the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer. PLoS One 2018;13:e0200658. [PMID: 30016349 DOI: 10.1371/journal.pone.0200658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
292 Łukaszewicz-Zając M, Gryko M, Pączek S, Szmitkowski M, Kędra B, Mroczko B. Matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor 2 (TIMP-2) in pancreatic cancer (PC). Oncotarget 2019;10:395-403. [PMID: 30719232 DOI: 10.18632/oncotarget.26571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
293 Narayanan V, Weekes CD. Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol. 2016;8:366-379. [PMID: 27096032 DOI: 10.4251/wjgo.v8.i4.366] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
294 Arslan AA, Helzlsouer KJ, Kooperberg C, Shu XO, Steplowski E, Bueno-de-Mesquita HB, Fuchs CS, Gross MD, Jacobs EJ, Lacroix AZ. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med. 2010;170:791-802. [PMID: 20458087 DOI: 10.1001/archinternmed.2010.63] [Cited by in Crossref: 228] [Cited by in F6Publishing: 198] [Article Influence: 20.7] [Reference Citation Analysis]
295 Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep. 2018;8:8666. [PMID: 29875415 DOI: 10.1038/s41598-018-26811-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
296 Segal L, Katz LS, Shapira H, Sandbank J, Geras-Raaka E, Gershengorn MC, Oron Y. PAR-3 knockdown enhances adhesion rate of PANC-1 cells via increased expression of integrinαv and E-cadherin. PLoS One 2014;9:e93879. [PMID: 24699825 DOI: 10.1371/journal.pone.0093879] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
297 Ma X, Li B, Liu J, Fu Y, Luo Y. Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E. J Exp Clin Cancer Res 2019;38:66. [PMID: 30744688 DOI: 10.1186/s13046-019-1053-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
298 Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J, Repasky EA. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 2005;3:22. [PMID: 15943879 DOI: 10.1186/1479-5876-3-22] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 4.8] [Reference Citation Analysis]
299 Gunda V, Souchek J, Abrego J, Shukla SK, Goode GD, Vernucci E, Dasgupta A, Chaika NV, King RJ, Li S, Wang S, Yu F, Bessho T, Lin C, Singh PK. MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer. Clin Cancer Res 2017;23:5881-91. [PMID: 28720669 DOI: 10.1158/1078-0432.CCR-17-1151] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
300 Chen H, Zhang Z, Lu Y, Song K, Liu X, Xia F, Sun W. Downregulation of ULK1 by microRNA-372 inhibits the survival of human pancreatic adenocarcinoma cells. Cancer Sci 2017;108:1811-9. [PMID: 28677209 DOI: 10.1111/cas.13315] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
301 Gidekel Friedlander SY, Chu GC, Snyder EL, Girnius N, Dibelius G, Crowley D, Vasile E, DePinho RA, Jacks T. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell. 2009;16:379-389. [PMID: 19878870 DOI: 10.1016/j.ccr.2009.09.027] [Cited by in Crossref: 214] [Cited by in F6Publishing: 202] [Article Influence: 17.8] [Reference Citation Analysis]
302 Sousa CM, Kimmelman AC. The complex landscape of pancreatic cancer metabolism. Carcinogenesis. 2014;35:1441-1450. [PMID: 24743516 DOI: 10.1093/carcin/bgu097] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 10.3] [Reference Citation Analysis]
303 Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, Honeywell RJ, Danesi R, Peters GJ, Giovannetti E. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther. 2012;11:1735-1746. [PMID: 22622284 DOI: 10.1158/1535-7163.mct-12-0037] [Cited by in Crossref: 60] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
304 Kimmelman AC, Hezel AF, Aguirre AJ, Zheng H, Paik JH, Ying H, Chu GC, Zhang JX, Sahin E, Yeo G, Ponugoti A, Nabioullin R, Deroo S, Yang S, Wang X, McGrath JP, Protopopova M, Ivanova E, Zhang J, Feng B, Tsao MS, Redston M, Protopopov A, Xiao Y, Futreal PA, Hahn WC, Klimstra DS, Chin L, DePinho RA. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci USA. 2008;105:19372-19377. [PMID: 19050074 DOI: 10.1073/pnas.0809966105] [Cited by in Crossref: 106] [Cited by in F6Publishing: 99] [Article Influence: 8.2] [Reference Citation Analysis]
305 Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, García-García E, López-Ríos F, Matsui W. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther. 2009;8:310-314. [PMID: 19174553 DOI: 10.1158/1535-7163.mct-08-0924] [Cited by in Crossref: 181] [Cited by in F6Publishing: 126] [Article Influence: 15.1] [Reference Citation Analysis]
306 Li M, Wang X, Li W, Li F, Yang H, Wang H, Brunicardi FC, Chen C, Yao Q, Fisher WE. Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer. Cancer Sci. 2008;99:2218-2223. [PMID: 18823376 DOI: 10.1111/j.1349-7006.2008.00940.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
307 Wang Y, Li J, Guo S, Ouyang Y, Yin L, Liu S, Zhao Z, Yang J, Huang W, Qin H, Zhao X, Ni B, Wang H. Lin28B facilitates the progression and metastasis of pancreatic ductal adenocarcinoma. Oncotarget 2017;8:60414-28. [PMID: 28947981 DOI: 10.18632/oncotarget.19578] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
308 Li Y, Zhang T, Schwartz SJ, Sun D. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function. Nutr Cancer 2011;63:1151-9. [PMID: 21875325 DOI: 10.1080/01635581.2011.596645] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
309 Dholakia AS, Kumar R, Raman SP, Moore JA, Ellsworth S, McNutt T, Laheru DA, Jaffee E, Cameron JL, Tran PT, Hobbs RF, Wolfgang CL, Herman JM. Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design. Int J Radiat Oncol Biol Phys 2013;87:1007-15. [PMID: 24267969 DOI: 10.1016/j.ijrobp.2013.09.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
310 Schick V, Franzius C, Beyna T, Oei ML, Schnekenburger J, Weckesser M, Domschke W, Schober O, Heindel W, Pohle T. Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur J Nucl Med Mol Imaging. 2008;35:1775-1785. [PMID: 18481063 DOI: 10.1007/s00259-008-0818-x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
311 Kakoza RM, Vollmer CM Jr, Stuart KE, Takoudes T, Hanto DW. Pancreatic adenocarcinoma in the pregnant patient: a case report and literature review. J Gastrointest Surg 2009;13:535-41. [PMID: 18815844 DOI: 10.1007/s11605-008-0697-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
312 Cyr DP, Truong JL, Lam-McCulloch J, Cleary SP, Karanicolas PJ. Canadian practice patterns for pancreaticoduodenectomy. Can J Surg 2015;58:121-7. [PMID: 25799248 DOI: 10.1503/cjs.011714] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
313 Cloyd JM, Nogueras-González GM, Prakash LR, Petzel MQB, Parker NH, Ngo-Huang AT, Fogelman D, Denbo JW, Garg N, Kim MP, Lee JE, Tzeng CD, Fleming JB, Katz MHG. Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. J Gastrointest Surg 2018;22:703-12. [PMID: 29230694 DOI: 10.1007/s11605-017-3618-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
314 Fesler A, Ju J. Development of microRNA-based therapy for pancreatic cancer. J Pancreatol 2019;2:147-51. [PMID: 32133215 DOI: 10.1097/jp9.0000000000000029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
315 Vittorio O, Cirillo G, Iemma F, Di Turi G, Jacchetti E, Curcio M, Barbuti S, Funel N, Parisi OI, Puoci F, Picci N. Dextran-catechin conjugate: a potential treatment against the pancreatic ductal adenocarcinoma. Pharm Res 2012;29:2601-14. [PMID: 22622510 DOI: 10.1007/s11095-012-0790-9] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]
316 Stark JL, Mehla K, Chaika N, Acton TB, Xiao R, Singh PK, Montelione GT, Powers R. Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancer. Biochemistry 2014;53:1360-72. [PMID: 24512202 DOI: 10.1021/bi401329a] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
317 Veite-Schmahl MJ, Rivers AC, Regan DP, Kennedy MA. The Mouse Model of Pancreatic Cancer Atlas (MMPCA) for classification of pancreatic cancer lesions: A large histological investigation of the Ptf1aCre/+;LSL-KrasG12D/+ transgenic mouse model of pancreatic cancer. PLoS One 2017;12:e0187552. [PMID: 29121082 DOI: 10.1371/journal.pone.0187552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
318 Xing H, Wang J, Wang Y, Tong M, Hu H, Huang C, Li D. Diagnostic Value of CA 19-9 and Carcinoembryonic Antigen for Pancreatic Cancer: A Meta-Analysis. Gastroenterol Res Pract. 2018;2018:8704751. [PMID: 30584422 DOI: 10.1155/2018/8704751] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
319 Zhu CL, Huang Q. Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.Dig Dis Sci. 2020;65:489-499. [PMID: 31441002 DOI: 10.1007/s10620-019-05797-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
320 Zhou RT, He M, Yu Z, Liang Y, Nie Y, Tai S, Teng CB. Baicalein inhibits pancreatic cancer cell proliferation and invasion via suppression of NEDD9 expression and its downstream Akt and ERK signaling pathways. Oncotarget 2017;8:56351-63. [PMID: 28915595 DOI: 10.18632/oncotarget.16912] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
321 Huang C, Li N, Li Z, Chang A, Chen Y, Zhao T, Li Y, Wang X, Zhang W, Wang Z, Luo L, Shi J, Yang S, Ren H, Hao J. Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Nat Commun 2017;8:14035. [PMID: 28102193 DOI: 10.1038/ncomms14035] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 14.0] [Reference Citation Analysis]
322 Feygenzon V, Loewenstein S, Lubezky N, Pasmanic-Chor M, Sher O, Klausner JM, Lahat G. Unique cellular interactions between pancreatic cancer cells and the omentum. PLoS One 2017;12:e0179862. [PMID: 28632775 DOI: 10.1371/journal.pone.0179862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
323 Shimasaki T, Kitano A, Motoo Y, Minamoto T. Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. J Carcinog 2012;11:15. [PMID: 23230392 DOI: 10.4103/1477-3163.100866] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
324 O'Kane GM, Ladak F, Gallinger S. Advances in the management of pancreatic ductal adenocarcinoma. CMAJ 2021;193:E844-51. [PMID: 34099468 DOI: 10.1503/cmaj.201450] [Reference Citation Analysis]
325 Däbritz J, Hänfler J, Preston R, Stieler J, Oettle H. Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br J Cancer 2005;92:405-12. [PMID: 15655549 DOI: 10.1038/sj.bjc.6602319] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 4.0] [Reference Citation Analysis]
326 Vorvis C, Koutsioumpa M, Iliopoulos D. Developments in miRNA gene signaling pathways in pancreatic cancer. Future Oncol. 2016;12:1135-1150. [PMID: 26984178 DOI: 10.2217/fon-2015-0050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
327 D'Aronzo M, Vinciguerra M, Mazza T, Panebianco C, Saracino C, Pereira SP, Graziano P, Pazienza V. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. Oncotarget 2015;6:18545-57. [PMID: 26176887 DOI: 10.18632/oncotarget.4186] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
328 Pan MR, Hsu MC, Luo CW, Chen LT, Shan YS, Hung WC. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. Oncotarget 2016;7:61136-51. [PMID: 27531902 DOI: 10.18632/oncotarget.11256] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
329 Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F, Rieken S, Weitz J, Werner J, Schirmacher P. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol. 2012;7:28. [PMID: 22385572 DOI: 10.1186/1748-717x-7-28] [Cited by in Crossref: 67] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
330 Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, Hildebrandt M, Ames M, Schaid D, Wang L. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 2008;68:7050-8. [PMID: 18757419 DOI: 10.1158/0008-5472.CAN-08-0405] [Cited by in Crossref: 123] [Cited by in F6Publishing: 89] [Article Influence: 9.5] [Reference Citation Analysis]
331 Meng Q, Shi S, Liang C, Liang D, Hua J, Zhang B, Xu J, Yu X. Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling. Oncogene 2018;37:5843-57. [DOI: 10.1038/s41388-018-0392-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 14.0] [Reference Citation Analysis]
332 Vaz J, Andersson R. Intervention on toll-like receptors in pancreatic cancer. World J Gastroenterol 2014;20:5808-17. [PMID: 24914341 DOI: 10.3748/wjg.v20.i19.5808] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
333 Wolpin BM, Chan AT, Hartge P, Chanock SJ, Kraft P, Hunter DJ, Giovannucci EL, Fuchs CS. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009;101:424-31. [PMID: 19276450 DOI: 10.1093/jnci/djp020] [Cited by in Crossref: 216] [Cited by in F6Publishing: 171] [Article Influence: 18.0] [Reference Citation Analysis]
334 Jawad ZAR, Theodorou IG, Jiao LR, Xie F. Highly Sensitive Plasmonic Detection of the Pancreatic Cancer Biomarker CA 19-9. Sci Rep 2017;7:14309. [PMID: 29085011 DOI: 10.1038/s41598-017-14688-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
335 Davila JA, Chiao EY, Hasche JC, Petersen NJ, McGlynn KA, Shaib YH. Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer. Pancreas. 2009;38:e18-e25. [PMID: 18797424 DOI: 10.1097/mpa.0b013e318187eb3f] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
336 Kelly KA, Bardeesy N, Anbazhagan R, Gurumurthy S, Berger J, Alencar H, Depinho RA, Mahmood U, Weissleder R. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med. 2008;5:e85. [PMID: 18416599 DOI: 10.1371/journal.pmed.0050085] [Cited by in Crossref: 159] [Cited by in F6Publishing: 147] [Article Influence: 12.2] [Reference Citation Analysis]
337 Higuera O, Ghanem I, Nasimi R, Prieto I, Koren L, Feliu J. Management of pancreatic cancer in the elderly. World J Gastroenterol 2016;22:764-75. [PMID: 26811623 DOI: 10.3748/wjg.v22.i2.764] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 49] [Article Influence: 16.3] [Reference Citation Analysis]
338 Li J, Kleeff J, Abiatari I, Kayed H, Giese NA, Felix K, Giese T, Büchler MW, Friess H. Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer 2005;4:14. [PMID: 15817123 DOI: 10.1186/1476-4598-4-14] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 4.1] [Reference Citation Analysis]
339 Jin X, Ye L, Lin M, Gu B, Wang J, He Y, Li W. lncRNA-CCHE1 is involved in migration and invasion but not in proliferation of pancreatic adenocarcinoma cells possibly by interacting with ROCK1. Oncol Lett 2019;18:1218-24. [PMID: 31423182 DOI: 10.3892/ol.2019.10416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
340 Zheng HC, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, Fujii C, Nomoto K, Mukaida N, Takano Y. Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol. 2008;134:481-488. [PMID: 17876606 DOI: 10.1007/s00432-007-0310-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
341 Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget 2017;8:44073-81. [PMID: 28454122 DOI: 10.18632/oncotarget.17237] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
342 Lin T, Ren Q, Zuo W, Jia R, Xie L, Lin R, Zhao H, Chen J, Lei Y, Wang P, Dong H, Huang L, Cai J, Peng Y, Yu Z, Tan J, Wang S. Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs. J Exp Clin Cancer Res 2019;38:150. [PMID: 30961642 DOI: 10.1186/s13046-019-1160-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
343 Kozikowski AP, Tapadar S, Luchini DN, Kim KH, Billadeau DD. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J Med Chem 2008;51:4370-3. [PMID: 18642892 DOI: 10.1021/jm8002894] [Cited by in Crossref: 136] [Cited by in F6Publishing: 119] [Article Influence: 10.5] [Reference Citation Analysis]
344 Unger K, Mehta KY, Kaur P, Wang Y, Menon SS, Jain SK, Moonjelly RA, Suman S, Datta K, Singh R, Fogel P, Cheema AK. Metabolomics based predictive classifier for early detection of pancreatic ductal adenocarcinoma. Oncotarget. 2018;9:23078-23090. [PMID: 29796173 DOI: 10.18632/oncotarget.25212] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
345 Yang Y, Yan S, Tian H, Bao Y. Macrophage inhibitory cytokine-1 vs carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies. Medicine (Baltimore). 2018;97:e9994. [PMID: 29489701 DOI: 10.1097/md.0000000000009994] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
346 Arnold S, Mira E, Muneer S, Korpanty G, Beck AW, Holloway SE, Mañes S, Brekken RA. Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Exp Biol Med (Maywood) 2008;233:860-73. [PMID: 18445772 DOI: 10.3181/0801-RM-12] [Cited by in Crossref: 48] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
347 Patel AK, Rodríguez-López JL, Bahary N, Zureikat AH, Burton SA, Heron DE, Olson AC. Patterns of Failure After Adjuvant Stereotactic Body Radiation Therapy for Pancreatic Cancer With Close or Positive Margins. Adv Radiat Oncol 2020;5:1197-205. [PMID: 33305081 DOI: 10.1016/j.adro.2020.08.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
348 Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, Karikari C, Alvarez H, Iacobuzio-Donahue C, Jimeno A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67:2187-2196. [PMID: 17332349 DOI: 10.1158/0008-5472.can-06-3281] [Cited by in Crossref: 495] [Cited by in F6Publishing: 285] [Article Influence: 35.4] [Reference Citation Analysis]
349 Li YH, Wang X, Pan Y, Lee DH, Chowdhury D, Kimmelman AC. Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response. PLoS One. 2012;7:e39588. [PMID: 22724027 DOI: 10.1371/journal.pone.0039588] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
350 Iwagami Y, Eguchi H, Nagano H, Akita H, Hama N, Wada H, Kawamoto K, Kobayashi S, Tomokuni A, Tomimaru Y. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer. 2013;109:502-511. [PMID: 23799850 DOI: 10.1038/bjc.2013.320] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 8.0] [Reference Citation Analysis]
351 Li YY, Mukaida N. Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression. World J Gastroenterol 2014;20:9392-404. [PMID: 25071334 DOI: 10.3748/wjg.v20.i28.9392] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
352 Reznik R, Hendifar AE, Tuli R. Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma. Front Physiol. 2014;5:87. [PMID: 24624093 DOI: 10.3389/fphys.2014.00087] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
353 Boreddy SR, Srivastava SK. Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model. Oncogene 2013;32:3980-91. [PMID: 22986522 DOI: 10.1038/onc.2012.413] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
354 Harpstrite SE, Gu H, Natarajan R, Sharma V. Interrogation of multidrug resistance (MDR1) P-glycoprotein (ABCB1) expression in human pancreatic carcinoma cells: correlation of 99mTc-Sestamibi uptake with western blot analysis. Nucl Med Commun 2014;35:1067-70. [PMID: 25036383 DOI: 10.1097/MNM.0000000000000158] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
355 van Duijneveldt G, Griffin MDW, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin Sci (Lond) 2020;134:2091-115. [PMID: 32808663 DOI: 10.1042/CS20191211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 10.0] [Reference Citation Analysis]
356 Cheng S, Swanson K, Eliaz I, McClintick JN, Sandusky GE, Sliva D. Pachymic acid inhibits growth and induces apoptosis of pancreatic cancer in vitro and in vivo by targeting ER stress. PLoS One 2015;10:e0122270. [PMID: 25915041 DOI: 10.1371/journal.pone.0122270] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
357 Miyatake Y, Ohta Y, Ikeshita S, Kasahara M. Anchorage-dependent multicellular aggregate formation induces a quiescent stem-like intractable phenotype in pancreatic cancer cells. Oncotarget 2018;9:29845-56. [PMID: 30042817 DOI: 10.18632/oncotarget.25732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
358 Park H, Bang JH, Nam AR, Eun Park J, Hua Jin M, Bang YJ, Oh DY. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. Sci Rep 2019;9:11131. [PMID: 31366979 DOI: 10.1038/s41598-019-47330-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
359 Heinrich S, Besselink M, Moehler M, van Laethem JL, Ducreux M, Grimminger P, Mittler J, Lang H, Lutz MP, Lesurtel M;  Scientific and Research Committee of the E-AHPBA and the EORTC pancreas working group. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. BMC Cancer. 2019;19:675. [PMID: 31288786 DOI: 10.1186/s12885-019-5889-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
360 Karna R, Javed A, Nasrullah A, Raja A, Arshad H. Pancreatic cancer Masquerading as lung nodules: A Diagnostic Dilemma. Respir Med Case Rep 2021;33:101453. [PMID: 34401292 DOI: 10.1016/j.rmcr.2021.101453] [Reference Citation Analysis]
361 Petrella F, Rimoldi I, Rizzo S, Spaggiari L. Mesenchymal Stromal Cells for Antineoplastic Drug Loading and Delivery. Medicines (Basel) 2017;4:E87. [PMID: 29168760 DOI: 10.3390/medicines4040087] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
362 Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant Treatment in Pancreatic Cancer. Front Oncol. 2020;10:245. [PMID: 32185128 DOI: 10.3389/fonc.2020.00245] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 29.0] [Reference Citation Analysis]
363 Roy SK, Srivastava RK, Shankar S. Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal. 2010;5:10. [PMID: 20642839 DOI: 10.1186/1750-2187-5-10] [Cited by in Crossref: 227] [Cited by in F6Publishing: 219] [Article Influence: 20.6] [Reference Citation Analysis]
364 Liao WC, Wang HP, Huang HY, Wu MS, Chiang H, Tien YW, Lin YL, Lin JT. CXCR4 expression predicts early liver recurrence and poor survival after resection of pancreatic adenocarcinoma. Clin Transl Gastroenterol 2012;3:e22. [PMID: 23238349 DOI: 10.1038/ctg.2012.18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
365 Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M, Scarpa A. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch. 2006;448:797-804. [PMID: 16568310 DOI: 10.1007/s00428-006-0173-x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
366 Lu Y, Wu X, Wang J. Correlation of miR-425-5p and IL-23 with pancreatic cancer. Oncol Lett 2019;17:4595-9. [PMID: 30944648 DOI: 10.3892/ol.2019.10099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
367 Kumar S, Inigo JR, Kumar R, Chaudhary AK, O'Malley J, Balachandar S, Wang J, Attwood K, Yadav N, Hochwald S, Wang X, Chandra D. Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. Cancer Lett 2018;413:82-93. [PMID: 29107110 DOI: 10.1016/j.canlet.2017.10.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
368 Sarkar S, Dutta D, Samanta SK, Bhattacharya K, Pal BC, Li J, Datta K, Mandal C, Mandal C. Oxidative inhibition of Hsp90 disrupts the super-chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivo. Int J Cancer 2013;132:695-706. [PMID: 22729780 DOI: 10.1002/ijc.27687] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
369 Al-Hajeili M, Azmi AS, Choi M. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Onco Targets Ther 2014;7:187-92. [PMID: 24523592 DOI: 10.2147/OTT.S40705] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
370 Tang MY, Zhang XM, Chen TW, Huang XH. Various diffusion magnetic resonance imaging techniques for pancreatic cancer. World J Radiol 2015;7:424-37. [PMID: 26753059 DOI: 10.4329/wjr.v7.i12.424] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
371 Singal V, Singal AK, Kuo YF. Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis. J Cancer Res Clin Oncol. 2012;138:715-722. [PMID: 22246279 DOI: 10.1007/s00432-012-1156-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
372 Shao Q, Liu F, Chung C, Elahi-Gedwillo K, Provenzano PP, Forsyth B, Bischof JC. Physical and Chemical Enhancement of and Adaptive Resistance to Irreversible Electroporation of Pancreatic Cancer. Ann Biomed Eng 2018;46:25-36. [PMID: 28983745 DOI: 10.1007/s10439-017-1932-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
373 Li JL, Cai Y, Zhang SW, Xiao SW, Li XF, Duan YJ, Li YH, Xu B, Yan K. Combination of Recombinant Adenovirus-p53 with Radiochemotherapy in Unresectable Pancreatic Carcinoma. Chin J Cancer Res 2011;23:194-200. [PMID: 23467436 DOI: 10.1007/s11670-011-0194-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
374 Choi HJ, Lee JW, Kang B, Song SY, Lee JD, Lee JH. Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy. Yonsei Med J 2014;55:1498-506. [PMID: 25323885 DOI: 10.3349/ymj.2014.55.6.1498] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
375 Song S, Zhou J, He S, Zhu D, Zhang Z, Zhao H, Wang Y, Li D. Expression levels of microRNA-375 in pancreatic cancer. Biomed Rep. 2013;1:393-398. [PMID: 24648956 DOI: 10.3892/br.2013.88] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
376 Kartalis N, Lindholm TL, Aspelin P, Permert J, Albiin N. Diffusion-weighted magnetic resonance imaging of pancreas tumours. Eur Radiol. 2009;19:1981-1990. [PMID: 19308414 DOI: 10.1007/s00330-009-1384-8] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 9.9] [Reference Citation Analysis]
377 Thakkar A, Sutaria D, Grandhi BK, Wang J, Prabhu S. The molecular mechanism of action of aspirin, curcumin and sulforaphane combinations in the chemoprevention of pancreatic cancer. Oncol Rep 2013;29:1671-7. [PMID: 23404329 DOI: 10.3892/or.2013.2276] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
378 Kulkarni P, Haldar MK, You S, Choi Y, Mallik S. Hypoxia-Responsive Polymersomes for Drug Delivery to Hypoxic Pancreatic Cancer Cells. Biomacromolecules 2016;17:2507-13. [PMID: 27303825 DOI: 10.1021/acs.biomac.6b00350] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 15.0] [Reference Citation Analysis]
379 Liu SL, Cai C, Yang ZY, Wu ZY, Wu XS, Wang XF, Dong P, Gong W. DGCR5 is activated by PAX5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/β-catenin pathway. Int J Biol Sci 2021;17:498-513. [PMID: 33613108 DOI: 10.7150/ijbs.55636] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
380 Salameh MA, Soares AS, Hockla A, Radisky DC, Radisky ES. The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity. Biochem J 2011;440:95-105. [PMID: 21806544 DOI: 10.1042/BJ20110788] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
381 Prasad R, Vaid M, Katiyar SK. Grape proanthocyanidin inhibit pancreatic cancer cell growth in vitro and in vivo through induction of apoptosis and by targeting the PI3K/Akt pathway. PLoS One 2012;7:e43064. [PMID: 22905202 DOI: 10.1371/journal.pone.0043064] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
382 Wang X, Kaczor-Urbanowicz KE, Wong DT. Salivary biomarkers in cancer detection. Med Oncol 2017;34:7. [PMID: 27943101 DOI: 10.1007/s12032-016-0863-4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 48] [Article Influence: 14.0] [Reference Citation Analysis]
383 Immervoll H, Hoem D, Kugarajh K, Steine SJ, Molven A. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch. 2006;448:788-796. [PMID: 16598499 DOI: 10.1097/mpa.0b013e3181b8feb0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
384 Sun C, Wang P, Dong W, Liu H, Sun J, Zhao L. LncRNA PVT1 promotes exosome secretion through YKT6, RAB7, and VAMP3 in pancreatic cancer. Aging (Albany NY) 2020;12:10427-40. [PMID: 32499447 DOI: 10.18632/aging.103268] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
385 Lu CH, Lin SH, Hsieh CH, Chen WT, Chao CY. Enhanced anticancer effects of low-dose curcumin with non-invasive pulsed electric field on PANC-1 cells. Onco Targets Ther 2018;11:4723-32. [PMID: 30127620 DOI: 10.2147/OTT.S166264] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
386 Valenzuela MM, Neidigh JW, Wall NR. Antimetabolite Treatment for Pancreatic Cancer. Chemotherapy (Los Angel) 2014;3:137. [PMID: 26161298 DOI: 10.4172/2167-7700.1000137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
387 Liu X, Zheng W, Wang W, Shen H, Liu L, Lou W, Wang X, Yang P. A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. Br J Cancer. 2017;117:1846-1854. [PMID: 29123261 DOI: 10.1038/bjc.2017.365] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]
388 Gaida MM, Welsch T, Herpel E, Tschaharganeh DF, Fischer L, Schirmacher P, Hänsch GM, Bergmann F. MHC class II expression in pancreatic tumors: a link to intratumoral inflammation. Virchows Arch 2012;460:47-60. [PMID: 22120497 DOI: 10.1007/s00428-011-1175-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
389 Morton JP, Klimstra DS, Mongeau ME, Lewis BC. Trp53 deletion stimulates the formation of metastatic pancreatic tumors. Am J Pathol 2008;172:1081-7. [PMID: 18310506 DOI: 10.2353/ajpath.2008.070778] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
390 Chen L, Qu C, Chen H, Xu L, Qi Q, Luo J, Wang K, Meng Z, Chen Z, Wang P, Liu L. Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer. PLoS One 2014;9:e96177. [PMID: 24781445 DOI: 10.1371/journal.pone.0096177] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
391 Huang C, Xie K. Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth Factor Rev 2012;23:25-35. [PMID: 22342309 DOI: 10.1016/j.cytogfr.2012.01.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
392 Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Rev Gastroenterol Hepatol. 2016;10:893-905. [PMID: 26881472 DOI: 10.1586/17474124.2016.1153424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
393 Ahn SS, Kim M, Choi J, Hong H, Chung YE, Lim JS. Indicative findings of pancreatic cancer in prediagnostic CT. Eur Radiol 2009;19:2448-55. [DOI: 10.1007/s00330-009-1422-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
394 Yin W, Kimbrough CW, Gomez-Gutierrez JG, Burns CT, Chuong P, Grizzle WE, McNally LR. Tumor specific liposomes improve detection of pancreatic adenocarcinoma in vivo using optoacoustic tomography. J Nanobiotechnology 2015;13:90. [PMID: 26627455 DOI: 10.1186/s12951-015-0139-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
395 Kishikawa T, Otsuka M, Yoshikawa T, Ohno M, Yamamoto K, Yamamoto N, Kotani A, Koike K. Quantitation of circulating satellite RNAs in pancreatic cancer patients. JCI Insight 2016;1:e86646. [PMID: 27699267 DOI: 10.1172/jci.insight.86646] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
396 Cogoi S, Xodo LE. G-quadruplex formation within the promoter of the KRAS proto-oncogene and its effect on transcription. Nucleic Acids Res 2006;34:2536-49. [PMID: 16687659 DOI: 10.1093/nar/gkl286] [Cited by in Crossref: 487] [Cited by in F6Publishing: 439] [Article Influence: 32.5] [Reference Citation Analysis]
397 Gao Z, Jiang W, Zhang S, Li P. The State of the Art on Blood MicroRNAs in Pancreatic Ductal Adenocarcinoma. Anal Cell Pathol (Amst) 2019;2019:9419072. [PMID: 31583198 DOI: 10.1155/2019/9419072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
398 Deeb D, Gao X, Arbab AS, Barton K, Dulchavsky SA, Gautam SC. CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer. Cancers (Basel) 2010;2:1779-93. [PMID: 21799944 DOI: 10.3390/cancers2041779] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
399 LaFemina J, Roberts PA, Hung YP, Gusella JF, Sahani D, Fernández-del Castillo C, Warshaw AL, Thayer SP. Identification of a novel kindred with familial pancreatitis and pancreatic cancer. Pancreatology 2009;9:273-9. [PMID: 19407482 DOI: 10.1159/000201553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
400 Bimonte S, Leongito M, Barbieri A, Del Vecchio V, Barbieri M, Albino V, Piccirillo M, Amore A, Di Giacomo R, Nasto A, Granata V, Petrillo A, Arra C, Izzo F. Inhibitory effect of (-)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth. Infect Agent Cancer 2015;10:22. [PMID: 26225138 DOI: 10.1186/s13027-015-0016-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
401 Domínguez-Muñoz JE, Nieto-Garcia L, López-Díaz J, Lariño-Noia J, Abdulkader I, Iglesias-Garcia J. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis. BMC Cancer 2018;18:534. [PMID: 29728096 DOI: 10.1186/s12885-018-4439-x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
402 Sun S, Osterman MD, Li M. Tissue specificity of DNA damage response and tumorigenesis. Cancer Biol Med 2019;16:396-414. [PMID: 31565474 DOI: 10.20892/j.issn.2095-3941.2019.0097] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
403 Nanashima A, Imamura N, Tsuchimochi Y, Hiyoshi M, Fujii Y. Combined resection of aberrant right hepatic artery without anastomosis in panceaticoduodenectomy for pancreatic head cancer: A case report. Int J Surg Case Rep 2016;25:66-70. [PMID: 27327560 DOI: 10.1016/j.ijscr.2016.05.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
404 Ahn SJ, Choi SJ, Kim HS. Time to Progression of Pancreatic Cancer: Evaluation with Multi-Detector Computed Tomography. J Gastrointest Cancer 2017;48:164-9. [PMID: 27699624 DOI: 10.1007/s12029-016-9876-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
405 Tian R, Wei LM, Qin RY, Li Y, Du ZY, Xia W, Shi CJ, Jin H. Proteome analysis of human pancreatic ductal adenocarcinoma tissue using two-dimensional gel electrophoresis and tandem mass spectrometry for identification of disease-related proteins. Dig Dis Sci 2008;53:65-72. [PMID: 17492507 DOI: 10.1007/s10620-007-9823-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
406 Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457-1461. [PMID: 19460966 DOI: 10.1126/science.1171362.inhibition] [Reference Citation Analysis]
407 Chen S, Dong H, Yang S, Guo H. Cathepsins in digestive cancers. Oncotarget 2017;8:41690-700. [PMID: 28402938 DOI: 10.18632/oncotarget.16677] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
408 Khalifa MA, Maksymov V, Rowsell C. Retroperitoneal margin of the pancreaticoduodenectomy specimen: anatomic mapping for the surgical pathologist. Virchows Arch. 2009;454:125-131. [PMID: 19066952 DOI: 10.1007/s00428-008-0711-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
409 Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, Aggarwal BB. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol 2017;174:1325-48. [PMID: 27638428 DOI: 10.1111/bph.13621] [Cited by in Crossref: 352] [Cited by in F6Publishing: 303] [Article Influence: 70.4] [Reference Citation Analysis]
410 Young K, Hughes DJ, Cunningham D, Starling N. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. Ther Adv Med Oncol. 2018;10:1758835918816281. [PMID: 30574212 DOI: 10.1177/1758835918816281] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
411 Wang C, Li J. Pathogenic Microorganisms and Pancreatic Cancer. Gastrointest Tumors 2015;2:41-7. [PMID: 26673459 DOI: 10.1159/000380896] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
412 Wan C, Shen Y, Yang T, Wang T, Chen L, Wen F. Diagnostic value of microRNA for pancreatic cancer: a meta-analysis. Arch Med Sci. 2012;8:749-755. [PMID: 23185182 DOI: 10.5114/aoms.2012.31609] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
413 Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol 2020;17:487-505. [PMID: 32393771 DOI: 10.1038/s41575-020-0300-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 75.0] [Reference Citation Analysis]
414 Nguyen TH, Park S, Hlaing KK, Kang HW. Temperature feedback-controlled photothermal treatment with diffusing applicator: theoretical and experimental evaluations. Biomed Opt Express 2016;7:1932-47. [PMID: 27231632 DOI: 10.1364/BOE.7.001932] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 3.6] [Reference Citation Analysis]
415 Sohrabi E, Rezaie E, Heiat M, Sefidi-Heris Y. An Integrated Data Analysis of mRNA, miRNA and Signaling Pathways in Pancreatic Cancer. Biochem Genet 2021. [PMID: 33813720 DOI: 10.1007/s10528-021-10062-x] [Reference Citation Analysis]
416 Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, Kim DW, Marshall J. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med. 2007;5:60. [PMID: 18039393 DOI: 10.1186/1479-5876-5-60] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
417 Chiang CC, Yeh CT, Hwang TL, Chu YD, Lim SN, Chen CW, Kuo CJ, Le PH, Chen TH, Lin WR. The GALNT14 Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma. J Clin Med 2019;8:E2225. [PMID: 31888240 DOI: 10.3390/jcm8122225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
418 Bailey KL, Carlson MA. Porcine Models of Pancreatic Cancer. Front Oncol 2019;9:144. [PMID: 30915276 DOI: 10.3389/fonc.2019.00144] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
419 Xing HB, Tong MT, Wang J, Hu H, Zhai CY, Huang CX, Li D. Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells. Biomed Res Int 2018;2018:3195025. [PMID: 29693005 DOI: 10.1155/2018/3195025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
420 Kuntz S, Kunz C, Rudloff S. Inhibition of pancreatic cancer cell migration by plasma anthocyanins isolated from healthy volunteers receiving an anthocyanin-rich berry juice. Eur J Nutr 2017;56:203-14. [PMID: 26476633 DOI: 10.1007/s00394-015-1070-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
421 Partecke IL, Kaeding A, Sendler M, Albers N, Kühn JP, Speerforck S, Roese S, Seubert F, Diedrich S, Kuehn S, Weiss UF, Mayerle J, Lerch MM, Hadlich S, Hosten N, Heidecke CD, Puls R, von Bernstorff W. In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model. BMC Cancer 2011;11:40. [PMID: 21276229 DOI: 10.1186/1471-2407-11-40] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
422 Lin L, Fan Y, Gao F, Jin L, Li D, Sun W, Li F, Qin P, Shi Q, Shi X, Du L. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy. Theranostics 2018;8:1923-39. [PMID: 29556365 DOI: 10.7150/thno.22834] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 20.0] [Reference Citation Analysis]
423 Santos-Rebelo A, Kumar P, Pillay V, Choonara YE, Eleutério C, Figueira M, Viana AS, Ascensão L, Molpeceres J, Rijo P, Correia I, Amaral J, Solá S, Rodrigues CMP, Gaspar MM, Reis CP. Development and Mechanistic Insight into the Enhanced Cytotoxic Potential of Parvifloron D Albumin Nanoparticles in EGFR-Overexpressing Pancreatic Cancer Cells. Cancers (Basel) 2019;11:E1733. [PMID: 31694306 DOI: 10.3390/cancers11111733] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
424 Logsdon CD, Abbruzzese JL. Chemoprevention of pancreatic cancer: ready for the clinic? Cancer Prev Res (Phila) 2010;3:1375-8. [PMID: 21084259 DOI: 10.1158/1940-6207.CAPR-10-0216] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
425 Nisar M, Paracha RZ, Arshad I, Adil S, Zeb S, Hanif R, Rafiq M, Hussain Z. Integrated Analysis of Microarray and RNA-Seq Data for the Identification of Hub Genes and Networks Involved in the Pancreatic Cancer. Front Genet 2021;12:663787. [PMID: 34262595 DOI: 10.3389/fgene.2021.663787] [Reference Citation Analysis]
426 Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014;124:1525-1536. [PMID: 24614108 DOI: 10.1172/jci73455] [Cited by in Crossref: 121] [Cited by in F6Publishing: 85] [Article Influence: 17.3] [Reference Citation Analysis]
427 Mechref Y, Hu Y, Garcia A, Hussein A. Identifying cancer biomarkers by mass spectrometry-based glycomics. Electrophoresis 2012;33:1755-67. [PMID: 22740464 DOI: 10.1002/elps.201100715] [Cited by in Crossref: 109] [Cited by in F6Publishing: 93] [Article Influence: 12.1] [Reference Citation Analysis]
428 Lee J, Hun Yun J, Lee J, Choi C, Hoon Kim J. Blockade of dual-specificity phosphatase 28 decreases chemo-resistance and migration in human pancreatic cancer cells. Sci Rep 2015;5:12296. [PMID: 26212664 DOI: 10.1038/srep12296] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
429 Zhang JH, Lai FJ, Chen H, Luo J, Zhang RY, Bu HQ, Wang ZH, Lin HH, Lin SZ. Involvement of the phosphoinositide 3-kinase/Akt pathway in apoptosis induced by capsaicin in the human pancreatic cancer cell line PANC-1. Oncol Lett 2013;5:43-8. [PMID: 23255891 DOI: 10.3892/ol.2012.991] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
430 Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W, Tonghua L. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 2009;8:125. [PMID: 20021699 DOI: 10.1186/1476-4598-8-125] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 6.7] [Reference Citation Analysis]
431 Zhang YJ, Wen CL, Qin YX, Tang XM, Shi MM, Shen BY, Fang Y. Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance. Oncol Rep 2017;38:3335-46. [PMID: 29039610 DOI: 10.3892/or.2017.6026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
432 Tjensvoll K, Lapin M, Buhl T, Oltedal S, Steen-Ottosen Berry K, Gilje B, Søreide JA, Javle M, Nordgård O, Smaaland R. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Mol Oncol 2016;10:635-43. [PMID: 26725968 DOI: 10.1016/j.molonc.2015.11.012] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 14.3] [Reference Citation Analysis]
433 Li J, Wu H, Li W, Yin L, Guo S, Xu X, Ouyang Y, Zhao Z, Liu S, Tian Y, Tian Z, Ju J, Ni B, Wang H. Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. Oncogene 2016;35:5501-14. [PMID: 27065335 DOI: 10.1038/onc.2016.90] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 18.4] [Reference Citation Analysis]
434 Zhao X, Zhang GB, Gan WJ, Xiong F, Li Z, Zhao H, Zhu DM, Zhang B, Zhang XG, Li DC. Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. Oncol Lett 2013;5:805-12. [PMID: 23426281 DOI: 10.3892/ol.2013.1118] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
435 Lou C, Zhang F, Yang M, Zhao J, Zeng W, Fang X, Zhang Y, Zhang C, Liang W. Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells. PLoS One 2012;7:e50956. [PMID: 23300530 DOI: 10.1371/journal.pone.0050956] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 7.1] [Reference Citation Analysis]
436 Kim SK, Wu CC, Horowitz DP. Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist. J Gastrointest Oncol 2016;7:479-86. [PMID: 27284482 DOI: 10.21037/jgo.2015.10.01] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
437 Alemar B, Gregório C, Ashton-Prolla P. miRNAs As Diagnostic and Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: A Review. Biomark Insights 2015;10:113-24. [PMID: 26688661 DOI: 10.4137/BMI.S27679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
438 Zhao X, Liu Y, Li Z, Zheng S, Wang Z, Li W, Bi Z, Li L, Jiang Y, Luo Y, Lin Q, Fu Z, Rufu C. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2018;22:655-667. [PMID: 28984028 DOI: 10.1111/jcmm.13351] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 17.3] [Reference Citation Analysis]
439 Lin R, Wang Y, Chen Q, Liu Z, Xiao S, Wang B, Shi B. TRPM2 promotes the proliferation and invasion of pancreatic ductal adenocarcinoma. Mol Med Rep. 2018;17:7537-7544. [PMID: 29620272 DOI: 10.3892/mmr.2018.8816] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
440 Caravatta L, Sallustio G, Pacelli F, Padula GD, Deodato F, Macchia G, Massaccesi M, Picardi V, Cilla S, Marinelli A, Cellini N, Valentini V, Morganti AG. Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer. Radiat Oncol 2012;7:86. [PMID: 22691275 DOI: 10.1186/1748-717X-7-86] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
441 Vanthomme K, Vandenheede H, Hagedoorn P, Gadeyne S. Evolution of educational inequalities in site-specific cancer mortality among Belgian men between the 1990s and 2000s using a "fundamental cause" perspective. BMC Cancer 2017;17:470. [PMID: 28679369 DOI: 10.1186/s12885-017-3461-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
442 Wang X, Wang J, Chen F, Zhong Z, Qi L. Detection of K-ras gene mutations in feces by magnetic nanoprobe in patients with pancreatic cancer: A preliminary study. Exp Ther Med 2018;15:527-31. [PMID: 29250161 DOI: 10.3892/etm.2017.5368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
443 Gujral TS, Kirschner MW. Hippo pathway mediates resistance to cytotoxic drugs. Proc Natl Acad Sci U S A 2017;114:E3729-38. [PMID: 28416665 DOI: 10.1073/pnas.1703096114] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
444 Gao S, Pan Y, Song L, Dong L, Weng LI, Wang P, Hua Y, Chen Z, Liu L. Nanog Predicts Poor Prognosis in Human Pancreatic Cancer and Is Downregulated by QingyihuaJi Formula in Pancreatic Cancer Stem Cells. Evid Based Complement Alternat Med 2016;2016:7028289. [PMID: 27829864 DOI: 10.1155/2016/7028289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
445 Jia L, Shang YY, Li YY. Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice. World J Gastroenterol. 2008;14:4377-4382. [PMID: 18666329 DOI: 10.3748/wjg.14.4377.] [Reference Citation Analysis]
446 Andersson G, Wennersten C, Borgquist S, Jirström K. Pancreatic cancer risk in relation to sex, lifestyle factors, and pre-diagnostic anthropometry in the Malmö Diet and Cancer Study. Biol Sex Differ 2016;7:66. [PMID: 27980714 DOI: 10.1186/s13293-016-0120-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
447 Hwang HK, Kim HI, Kim SH, Choi J, Kang CM, Kim KS, Lee WJ. Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3(+))/activated cytotoxic T lymphocyte (granzyme B(+)) ratio on resected left-sided pancreatic cancer. Oncol Lett. 2016;12:4477-4484. [PMID: 28105157 DOI: 10.3892/ol.2016.5252] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
448 Malinka T, Klein F, Denecke T, Pelzer U, Pratschke J, Bahra M. The Falciform Ligament for Mesenteric and Portal Vein Reconstruction in Local Advanced Pancreatic Tumor: A Surgical Guide and Single-Center Experience. HPB Surg 2018;2018:2943879. [PMID: 30364084 DOI: 10.1155/2018/2943879] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
449 Zhang Y, Bharadwaj U, Logsdon CD, Chen C, Yao Q, Li M. ZIP4 regulates pancreatic cancer cell growth by activating IL-6/STAT3 pathway through zinc finger transcription factor CREB. Clin Cancer Res. 2010;16:1423-1430. [PMID: 20160059 DOI: 10.1158/1078-0432.CCR-09-2405] [Cited by in Crossref: 57] [Cited by in F6Publishing: 38] [Article Influence: 5.2] [Reference Citation Analysis]
450 Spano C, Grisendi G, Golinelli G, Rossignoli F, Prapa M, Bestagno M, Candini O, Petrachi T, Recchia A, Miselli F, Rovesti G, Orsi G, Maiorana A, Manni P, Veronesi E, Piccinno MS, Murgia A, Pinelli M, Horwitz EM, Cascinu S, Conte P, Dominici M. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Sci Rep 2019;9:1788. [PMID: 30742129 DOI: 10.1038/s41598-018-37433-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
451 Zhou M, Diao Z, Yue X, Chen Y, Zhao H, Cheng L, Sun J. Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer. Oncotarget. 2016;7:56383-56394. [PMID: 27487139 DOI: 10.18632/oncotarget.10891] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 30.3] [Reference Citation Analysis]
452 Strom T, Hoffe SE, Fulp W, Frakes J, Coppola D, Springett GM, Malafa MP, Harris CL, Eschrich SA, Torres-Roca JF, Shridhar R. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Radiother Oncol 2015;117:159-64. [PMID: 26235848 DOI: 10.1016/j.radonc.2015.07.018] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 6.7] [Reference Citation Analysis]
453 Shirk AJ, Kuver R. Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cells. BMC Gastroenterol. 2005;5:12. [PMID: 15801978 DOI: 10.1186/1471-230X-5-12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
454 Jiang H, Wu D, Ma D, Lin G, Liang J, Jin J. Association between X-ray repair cross-complementation group 1 rs25487 polymorphism and pancreatic cancer risk. Tumour Biol 2013;34:3417-21. [PMID: 23807675 DOI: 10.1007/s13277-013-0914-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
455 Colbert LE, Hall WA, Nickleach D, Switchenko J, Kooby DA, Liu Y, Gillespie T, Lipscomb J, Kauh J, Landry JC. Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. Cancer 2014;120:499-506. [PMID: 24390739 DOI: 10.1002/cncr.28530] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
456 Combs SE, Habermehl D, Kessel K, Bergmann F, Werner J, Brecht I, Schirmacher P, Jäger D, Büchler MW, Debus J. Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3D-treated patient cohort. Strahlenther Onkol 2013;189:738-44. [PMID: 23896630 DOI: 10.1007/s00066-013-0391-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
457 Lynch HT, Fusaro RM, Lynch JF, Brand R. Pancreatic cancer and the FAMMM syndrome. Familial Cancer 2008;7:103-12. [DOI: 10.1007/s10689-007-9166-4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 5.5] [Reference Citation Analysis]
458 Mao Y, Fang L, Ai L, Li C, Wang Z, Wu J, Bai J, Li F. An in vivo study of the effects on serum glucose, amylase and histopathology of the feline pancreatic tissue treated by focused ultrasound. PLoS One 2014;9:e88815. [PMID: 24558434 DOI: 10.1371/journal.pone.0088815] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
459 Wang SQ, Liu Y, Yao MY, Jin J. Eukaryotic Translation Initiation Factor 3a (eIF3a) Promotes Cell Proliferation and Motility in Pancreatic Cancer. J Korean Med Sci 2016;31:1586-94. [PMID: 27550487 DOI: 10.3346/jkms.2016.31.10.1586] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
460 Pevsner-Fischer M, Tuganbaev T, Meijer M, Zhang SH, Zeng ZR, Chen MH, Elinav E. Role of the microbiome in non-gastrointestinal cancers. World J Clin Oncol 2016;7:200-13. [PMID: 27081642 DOI: 10.5306/wjco.v7.i2.200] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
461 Kagedan DJ, Raju RS, Dixon ME, Shin E, Li Q, Liu N, Elmi M, El-Sedfy A, Paszat L, Kiss A, Earle CC, Mittmann N, Coburn NG. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. HPB (Oxford) 2016;18:339-47. [PMID: 27037203 DOI: 10.1016/j.hpb.2015.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
462 Lochan R, Daly AK, Reeves HL, Charnley RM. Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma. J Oncol. 2011;2011:215985. [PMID: 21547248 DOI: 10.1155/2011/215985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
463 Kim SJ, Park JY, Hwang HS, Kang CM. Complete response of locally advanced left-sided pancreatic cancer after modified FOLFIRINOX chemotherapy followed by conversion surgery: A case report. Ann Hepatobiliary Pancreat Surg 2021;25:390-4. [PMID: 34402441 DOI: 10.14701/ahbps.2021.25.3.390] [Reference Citation Analysis]
464 Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, Brentnall TA, Lynch HT, Canto MI;  Participants of the Fourth International Symposium of Inherited Diseases of the Pancreas. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut. 2007;56:1460-1469. [PMID: 17872573 DOI: 10.1136/gut.2006.108456] [Cited by in Crossref: 204] [Cited by in F6Publishing: 174] [Article Influence: 14.6] [Reference Citation Analysis]
465 Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, Brunicardi FC, Chen C, Yao Q. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008;7:286-96. [PMID: 18281514 DOI: 10.1158/1535-7163.MCT-07-0483] [Cited by in Crossref: 107] [Cited by in F6Publishing: 79] [Article Influence: 8.2] [Reference Citation Analysis]
466 Li Y, Li P, Jin M, Jiang C, Gao Z. Docetaxel-encapsulating small-sized polymeric micelles with higher permeability and its efficacy on the orthotopic transplantation model of pancreatic ductal adenocarcinoma. Int J Mol Sci 2014;15:23571-88. [PMID: 25526569 DOI: 10.3390/ijms151223571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
467 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol. 2014;20:11142-11159. [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 64] [Article Influence: 12.3] [Reference Citation Analysis]
468 Banerjee S, Saluja A. Minnelide, a novel drug for pancreatic and liver cancer. Pancreatology 2015;15:S39-43. [PMID: 26122306 DOI: 10.1016/j.pan.2015.05.472] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
469 Wolpin BM, Chan AT, Hartge P, Chanock SJ, Kraft P, Hunter DJ, Giovannucci EL, Fuchs CS. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2009;101:424-431. [PMID: 19276450 DOI: 10.1093/dnci/djp020] [Reference Citation Analysis]
470 Ganepola GA, Rutledge JR, Suman P, Yiengpruksawan A, Chang DH. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. World J Gastrointest Oncol. 2014;6:22-33. [PMID: 24578785 DOI: 10.4251/wjgo.v6.i1.22] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 62] [Article Influence: 10.4] [Reference Citation Analysis]
471 Wiktor-Brown DM, Hendricks CA, Olipitz W, Engelward BP. Age-dependent accumulation of recombinant cells in the mouse pancreas revealed by in situ fluorescence imaging. Proc Natl Acad Sci U S A 2006;103:11862-7. [PMID: 16882718 DOI: 10.1073/pnas.0604943103] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
472 Liao MY, Lai JK, Kuo MY, Lu RM, Lin CW, Cheng PC, Liang KH, Wu HC. An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. Oncotarget 2015;6:24947-68. [PMID: 26317650 DOI: 10.18632/oncotarget.4453] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
473 Weissmueller S, Manchado E, Saborowski M, Morris JP, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell. 2014;157:382-394. [PMID: 24725405 DOI: 10.1016/j.cell.2014.01.066] [Cited by in Crossref: 286] [Cited by in F6Publishing: 288] [Article Influence: 40.9] [Reference Citation Analysis]
474 Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med 2019;25:620-7. [PMID: 30833748 DOI: 10.1038/s41591-019-0367-9] [Cited by in Crossref: 213] [Cited by in F6Publishing: 177] [Article Influence: 106.5] [Reference Citation Analysis]
475 Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, Marubashi S, Takemasa I, Nagano H, Dono K, Nakamori S, Monden M, Mori M, Doki Y, Bepler G. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene. 2009;28:2903-2909. [PMID: 19543324 DOI: 10.1038/onc.2009.158] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 7.0] [Reference Citation Analysis]
476 Ozaki T, Yu M, Yin D, Sun D, Zhu Y, Bu Y, Sang M. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations. BMC Cancer 2018;18:309. [PMID: 29558908 DOI: 10.1186/s12885-018-4217-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
477 Partecke LI, Käding A, Trung DN, Diedrich S, Sendler M, Weiss F, Kühn JP, Mayerle J, Beyer K, von Bernstorff W, Heidecke CD, Keßler W. Subdiaphragmatic vagotomy promotes tumor growth and reduces survival via TNFα in a murine pancreatic cancer model. Oncotarget 2017;8:22501-12. [PMID: 28160574 DOI: 10.18632/oncotarget.15019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
478 Karikari CA, Roy I, Tryggestad E, Feldmann G, Pinilla C, Welsh K, Reed JC, Armour EP, Wong J, Herman J. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther. 2007;6:957-966. [PMID: 17339366 DOI: 10.1158/1535-7163.mct-06-0634] [Cited by in Crossref: 57] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
479 Arora S, Bhardwaj A, Srivastava SK, Singh S, McClellan S, Wang B, Singh AP. Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. PLoS One 2011;6:e21573. [PMID: 21720559 DOI: 10.1371/journal.pone.0021573] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 9.7] [Reference Citation Analysis]
480 Porta M, Fabregat X, Malats N, Guarner L, Carrato A, de Miguel A, Ruiz L, Jariod M, Costafreda S, Coll S. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005;7:189-197. [PMID: 15960930 DOI: 10.1007/bf02712816] [Cited by in Crossref: 132] [Cited by in F6Publishing: 62] [Article Influence: 8.3] [Reference Citation Analysis]
481 Foo WC, Rashid A, Wang H, Katz MH, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Fleming JB, Wang H. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol. 2013;44:1024-1030. [PMID: 23260327 DOI: 10.1016/j.humpath.2012.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
482 Liang K, Liu F, Fan J, Sun D, Liu C, Lyon CJ, Bernard DW, Li Y, Yokoi K, Katz MH, Koay EJ, Zhao Z, Hu Y. Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring. Nat Biomed Eng 2017;1:0021. [PMID: 28791195 DOI: 10.1038/s41551-016-0021] [Cited by in Crossref: 158] [Cited by in F6Publishing: 144] [Article Influence: 39.5] [Reference Citation Analysis]
483 Simionato F, Zecchetto C, Merz V, Cavaliere A, Casalino S, Gaule M, D'Onofrio M, Malleo G, Landoni L, Esposito A, Marchegiani G, Casetti L, Tuveri M, Paiella S, Scopelliti F, Giardino A, Frigerio I, Regi P, Capelli P, Gobbo S, Gabbrielli A, Bernardoni L, Fedele V, Rossi I, Piazzola C, Giacomazzi S, Pasquato M, Gianfortone M, Milleri S, Milella M, Butturini G, Salvia R, Bassi C, Melisi D. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Ther Adv Med Oncol. 2020;12:1758835920947969. [PMID: 33403007 DOI: 10.1177/1758835920947969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
484 Betancourt R, Zou W, Plastaras JP, Metz JM, Teo BK, Kassaee A. Abdominal and pancreatic motion correlation using 4D CT, 4D transponders, and a gating belt. J Appl Clin Med Phys 2013;14:4060. [PMID: 23652242 DOI: 10.1120/jacmp.v14i3.4060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
485 Guimaraes AR, Rakhlin E, Weissleder R, Thayer SP. Magnetic resonance imaging monitors physiological changes with antihedgehog therapy in pancreatic adenocarcinoma xenograft model. Pancreas 2008;37:440-4. [PMID: 18953259 DOI: 10.1097/MPA.0b013e31817c5113] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
486 Singh BN, Fu J, Srivastava RK, Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One. 2011;6:e27306. [PMID: 22087285 DOI: 10.1371/journal.pone.0027306] [Cited by in Crossref: 136] [Cited by in F6Publishing: 129] [Article Influence: 13.6] [Reference Citation Analysis]
487 Gao X, Deeb D, Liu Y, Liu P, Zhang Y, Shaw J, Gautam SC. CDDO-Me inhibits tumor growth and prevents recurrence of pancreatic ductal adenocarcinoma. Int J Oncol. 2015;47:2100-2106. [PMID: 26497549 DOI: 10.3892/ijo.2015.3212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
488 Srivastava SK, Bhardwaj A, Singh S, Arora S, Wang B, Grizzle WE, Singh AP. MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis. 2011;32:1832-1839. [PMID: 21983127 DOI: 10.1093/carcin/bgr223] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 10.9] [Reference Citation Analysis]
489 Hippisley-Cox J, Coupland C. Identifying patients with suspected pancreatic cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2012;62:e38-45. [PMID: 22520674 DOI: 10.3399/bjgp12X616355] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
490 Chen J, Weihs D, Vermolen FJ. Computational modeling of therapy on pancreatic cancer in its early stages. Biomech Model Mechanobiol 2020;19:427-44. [PMID: 31501963 DOI: 10.1007/s10237-019-01219-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
491 Fu XF, Zhao HC, Yang CL, Chen CZ, Wang K, Gao F, Tian YZ, Zhao HL. MicroRNA-203-3p inhibits the proliferation, invasion and migration of pancreatic cancer cells by downregulating fibroblast growth factor 2. Oncol Lett 2021;22:626. [PMID: 34267818 DOI: 10.3892/ol.2021.12887] [Reference Citation Analysis]
492 Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, Kim J, Helm J, Valone T, Springett G. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol 2011;104:155-61. [PMID: 21520097 DOI: 10.1002/jso.21954] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 7.2] [Reference Citation Analysis]
493 Irizarry MC, Webb DJ, Boudiaf N, Logie J, Habel LA, Udaltsova N, Friedman GD. Risk of cancer in patients exposed to gabapentin in two electronic medical record systems. Pharmacoepidemiol Drug Saf 2012;21:214-25. [PMID: 22144034 DOI: 10.1002/pds.2266] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
494 Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, Matsui W, Eberhart CG, Maitra A, Feldmann G. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res. 2009;15:2291-2301. [PMID: 19258443 DOI: 10.1158/1078-0432.ccr-08-2004] [Cited by in Crossref: 126] [Cited by in F6Publishing: 84] [Article Influence: 10.5] [Reference Citation Analysis]
495 West DL, White SB, Zhang Z, Larson AC, Omary RA. Assessment and optimization of electroporation-assisted tumoral nanoparticle uptake in a nude mouse model of pancreatic ductal adenocarcinoma. Int J Nanomedicine 2014;9:4169-76. [PMID: 25214781 DOI: 10.2147/IJN.S63324] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
496 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets 2012;13:811-28. [PMID: 22458528 DOI: 10.2174/138945012800564068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
497 Song W, Tian C, Wang K, Zhang RJ, Zou SB. Preoperative platelet lymphocyte ratio as independent predictors of prognosis in pancreatic cancer: A systematic review and meta-analysis. PLoS One 2017;12:e0178762. [PMID: 28575033 DOI: 10.1371/journal.pone.0178762] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
498 Yang J, Ye Z, Mei D, Gu H, Zhang J. Long noncoding RNA DLX6-AS1 promotes tumorigenesis by modulating miR-497-5p/FZD4/FZD6/Wnt/β-catenin pathway in pancreatic cancer. Cancer Manag Res 2019;11:4209-21. [PMID: 31118816 DOI: 10.2147/CMAR.S194453] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
499 Shi B, Wang X, Han X, Liu P, Wei W, Li Y. Functional modules analysis based on coexpression network in pancreatic ductal adenocarcinoma. Pathol Oncol Res 2014;20:293-9. [PMID: 24185439 DOI: 10.1007/s12253-013-9694-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
500 Murray OT, Wong CC, Vrankova K, Rigas B. Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate. Int J Oncol 2014;44:521-9. [PMID: 24284479 DOI: 10.3892/ijo.2013.2190] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
501 Krishnamoorthy M, Lenehan JG, Burton JP, Maleki Vareki S. Immunomodulation in Pancreatic Cancer. Cancers (Basel) 2020;12:E3340. [PMID: 33198059 DOI: 10.3390/cancers12113340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
502 Gaviraghi M, Tunici P, Valensin S, Rossi M, Giordano C, Magnoni L, Dandrea M, Montagna L, Ritelli R, Scarpa A, Bakker A. Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells. Biosci Rep 2011;31:45-55. [PMID: 20426768 DOI: 10.1042/BSR20100018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
503 Raj D, Yang MH, Rodgers D, Hampton EN, Begum J, Mustafa A, Lorizio D, Garces I, Propper D, Kench JG, Kocher HM, Young TS, Aicher A, Heeschen C. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut. 2019;68:1052-1064. [PMID: 30121627 DOI: 10.1136/gutjnl-2018-316595] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 17.7] [Reference Citation Analysis]
504 Amaral AF, Porta M, Silverman DT, Milne RL, Kogevinas M, Rothman N, Cantor KP, Jackson BP, Pumarega JA, López T. Pancreatic cancer risk and levels of trace elements. Gut. 2012;61:1583-1588. [PMID: 22184070 DOI: 10.1136/gutjnl-2011-301086] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 6.1] [Reference Citation Analysis]
505 Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan Z, Ai K. H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2-mediated EMT. Tumor Biol 2014;35:9163-9. [DOI: 10.1007/s13277-014-2185-5] [Cited by in Crossref: 183] [Cited by in F6Publishing: 177] [Article Influence: 26.1] [Reference Citation Analysis]
506 Jia L, Shang YY, Li YY. Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice. World J Gastroenterol. 2008;14:4377-4382. [PMID: 18666329 DOI: 10.3748/wjg.14.4377] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
507 El-Kady A, Sun Y, Li YX, Liao DJ. Cyclin D1 inhibits whereas c-Myc enhances the cytotoxicity of cisplatin in mouse pancreatic cancer cells via regulation of several members of the NF-κB and Bcl-2 families. J Carcinog. 2011;10:24. [PMID: 22190866 DOI: 10.4103/1477-3163.90437] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
508 Vaziri-Gohar A, Zarei M, Brody JR, Winter JM. Metabolic Dependencies in Pancreatic Cancer. Front Oncol. 2018;8:617. [PMID: 30631752 DOI: 10.3389/fonc.2018.00617] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
509 Hu P, Chen X, Sun J, Bie P, Zhang LD. siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo. Biosci Rep 2015;35:e00170. [PMID: 25370920 DOI: 10.1042/BSR20140124] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
510 Shi S, Cao H. Shikonin promotes autophagy in BXPC-3 human pancreatic cancer cells through the PI3K/Akt signaling pathway. Oncol Lett 2014;8:1087-9. [PMID: 25120662 DOI: 10.3892/ol.2014.2293] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
511 Kariolis MS, Miao YR, Diep A, Nash SE, Olcina MM, Jiang D, Jones DS 2nd, Kapur S, Mathews II, Koong AC, Rankin EB, Cochran JR, Giaccia AJ. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies. J Clin Invest 2017;127:183-98. [PMID: 27893463 DOI: 10.1172/JCI85610] [Cited by in Crossref: 50] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
512 Tobi M, Kim M, Weinstein DH, Rambus MA, Hatfield J, Adsay NV, Levi E, Evans D, Lawson MJ, Fligiel S. Prospective markers for early diagnosis and prognosis of sporadic pancreatic ductal adenocarcinoma. Dig Dis Sci. 2013;58:744-750. [PMID: 23001406 DOI: 10.1007/s10620-012-2387-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
513 Chan K, Shah K, Lien K, Coyle D, Lam H, Ko YJ. A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. PLoS One. 2014;9:e108749. [PMID: 25286060 DOI: 10.1371/journal.pone.0108749] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
514 Jung W, Jang JY, Kang MJ, Chang YR, Shin YC, Chang J, Kim SW. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients. HPB (Oxford) 2016;18:57-64. [PMID: 26776852 DOI: 10.1016/j.hpb.2015.06.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
515 Kagedan DJ, Dixon ME, Raju RS, Li Q, Elmi M, Shin E, Liu N, El-Sedfy A, Paszat L, Kiss A, Earle CC, Mittmann N, Coburn NG. Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level. Curr Oncol 2016;23:334-42. [PMID: 27803598 DOI: 10.3747/co.23.3205] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
516 Meng Q, Liang C, Hua J, Zhang B, Liu J, Zhang Y, Wei M, Yu X, Xu J, Shi S. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. Theranostics 2020;10:3967-79. [PMID: 32226532 DOI: 10.7150/thno.40566] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 22.0] [Reference Citation Analysis]
517 Amin S, Baine M, Meza J, Lin C. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis. BMC Cancer 2020;20:538. [PMID: 32517661 DOI: 10.1186/s12885-020-07016-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
518 Singh RR, Reindl KM. Glutathione S-Transferases in Cancer. Antioxidants (Basel) 2021;10:701. [PMID: 33946704 DOI: 10.3390/antiox10050701] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
519 Khanna A, Mahalingam K, Chakrabarti D, Periyasamy G. Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells. Cell Mol Biol Lett. 2011;16:101-113. [PMID: 21225469 DOI: 10.2478/s11658-010-0043-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
520 Liu Z, Pouli D, Sood D, Sundarakrishnan A, Hui Mingalone CK, Arendt LM, Alonzo C, Quinn KP, Kuperwasser C, Zeng L, Schnelldorfer T, Kaplan DL, Georgakoudi I. Automated quantification of three-dimensional organization of fiber-like structures in biological tissues. Biomaterials 2017;116:34-47. [PMID: 27914265 DOI: 10.1016/j.biomaterials.2016.11.041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
521 Pal K, Pletnev AA, Dutta SK, Wang E, Zhao R, Baral A, Yadav VK, Aggarwal S, Krishnaswamy S, Alkharfy KM, Chowdhury S, Spaller MR, Mukhopadhyay D. Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth. Mol Cancer Ther 2014;13:2264-75. [PMID: 25125675 DOI: 10.1158/1535-7163.MCT-14-0291] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
522 Song B, Liu XS, Rice SJ, Kuang S, Elzey BD, Konieczny SF, Ratliff TL, Hazbun T, Chiorean EG, Liu X. Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. Mol Cancer Ther 2013;12:58-68. [PMID: 23188630 DOI: 10.1158/1535-7163.MCT-12-0632] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
523 Ohhashi S, Ohuchida K, Mizumoto K, Egami T, Yu J, Cui L, Toma H, Takahata S, Nabae T, Tanaka M. Midkine mRNA is overexpressed in pancreatic cancer. Dig Dis Sci. 2009;54:811-815. [PMID: 18712601 DOI: 10.1007/s10620-008-0434-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
524 Lemke J, Scheele J, Kapapa T, Wirtz CR, Henne-Bruns D, Kornmann M. Brain metastasis in pancreatic cancer. Int J Mol Sci. 2013;14:4163-4173. [PMID: 23429199 DOI: 10.3390/ijms14024163] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
525 Jansen RJ, Robinson DP, Stolzenberg-Solomon RZ, Bamlet WR, de Andrade M, Oberg AL, Hammer TJ, Rabe KG, Anderson KE, Olson JE, Sinha R, Petersen GM. Fruit and vegetable consumption is inversely associated with having pancreatic cancer. Cancer Causes Control 2011;22:1613-25. [PMID: 21915615 DOI: 10.1007/s10552-011-9838-0] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
526 Xie CG, Wei SM, Chen JM, Xu XF, Cai JT, Chen QY, Jia LT. Down-regulation of GEP100 causes increase in E-cadherin levels and inhibits pancreatic cancer cell invasion. PLoS One. 2012;7:e37854. [PMID: 22662237 DOI: 10.1371/journal.pone.0037854] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
527 Su D, Jiao SC, Wang LJ, Shi WW, Long YY, Li J, Bai L. Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Tumour Biol. 2014;35:2313-2318. [PMID: 24142531 DOI: 10.1007/s13277-013-1306-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
528 Wang XY, Yang F, Jin C, Fu DL. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol 2014;20:15580-9. [PMID: 25400441 DOI: 10.3748/wjg.v20.i42.15580] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
529 Feng J, Yu J, Pan X, Li Z, Chen Z, Zhang W, Wang B, Yang L, Xu H, Zhang G, Xu Z. HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. Oncotarget. 2014;5:5832-5844. [PMID: 25071021 DOI: 10.18632/oncotarget.2200] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
530 Bo H, Gao L, Chen Y, Zhang J, Zhu M. Upregulation of the expression of Wnt5a promotes the proliferation of pancreatic cancer cells in vitro and in a nude mouse model. Mol Med Rep 2016;13:1163-71. [PMID: 26648282 DOI: 10.3892/mmr.2015.4642] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
531 Emamzadeh M, Pasparakis G. Polymer coated gold nanoshells for combinational photochemotherapy of pancreatic cancer with gemcitabine. Sci Rep 2021;11:9404. [PMID: 33931720 DOI: 10.1038/s41598-021-88909-x] [Reference Citation Analysis]
532 Guweidhi A, Kleeff J, Adwan H, Giese NA, Wente MN, Giese T, Büchler MW, Berger MR, Friess H. Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg. 2005;242:224-234. [PMID: 16041213 DOI: 10.1097/01.sla.0000171866.45848.68] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 4.4] [Reference Citation Analysis]
533 Ong SL, Garcea G, Thomasset SC, Mann CD, Neal CP, Abu Amara M, Dennison AR, Berry DP. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma. J Gastrointest Surg 2008;12:1068-73. [PMID: 18043987 DOI: 10.1007/s11605-007-0422-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
534 Akahori T, Sho M, Kinoshita S, Nagai M, Nishiwada S, Tanaka T, Tamamoto T, Ohbayashi C, Hasegawa M, Kichikawa K, Nakajima Y. Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. World J Surg 2015;39:2975-82. [PMID: 26296840 DOI: 10.1007/s00268-015-3205-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
535 Chargari C, Campana F, Beuzeboc P, Zefkili S, Kirova YM. Preliminary experience of helical tomotherapy for locally advanced pancreatic cancer. World J Gastroenterol 2009;15:4444-5. [PMID: 19764098 DOI: 10.3748/wjg.15.4444] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
536 Zhan Q, Shen B, Deng X, Chen H, Jin J, Zhang X, Peng C, Li H. Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery. Int J Nanomedicine 2013;8:2465-72. [PMID: 23885173 DOI: 10.2147/IJN.S47666] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
537 Reyes-Gibby CC, Chan W, Abbruzzese JL, Xiong HQ, Ho L, Evans DB, Varadhachary G, Bhat S, Wolff RA, Crane C. Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. J Pain Symptom Manage 2007;34:244-52. [PMID: 17513082 DOI: 10.1016/j.jpainsymman.2006.11.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
538 Tjomsland V, Spångeus A, Sandström P, Borch K, Messmer D, Larsson M. Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor. PLoS One 2010;5:e13441. [PMID: 20976171 DOI: 10.1371/journal.pone.0013441] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
539 Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, DePinho RA. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006;20:3130-3146. [PMID: 17114584 DOI: 10.1101/gad.1478706] [Cited by in Crossref: 432] [Cited by in F6Publishing: 386] [Article Influence: 28.8] [Reference Citation Analysis]
540 Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, Manabe T. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression. BMC Cell Biol. 2006;7:8. [PMID: 16504015 DOI: 10.1186/1471-2121-7-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
541 Wang P, Zhuang L, Zhang J, Fan J, Luo J, Chen H, Wang K, Liu L, Chen Z, Meng Z. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol. 2013;7:334-345. [PMID: 23177026 DOI: 10.1016/j.molonc.2012.10.011] [Cited by in Crossref: 109] [Cited by in F6Publishing: 107] [Article Influence: 12.1] [Reference Citation Analysis]
542 Shi H, Li J, Fu D. Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. J Cancer Res Clin Oncol 2016;142:1137-61. [PMID: 26250876 DOI: 10.1007/s00432-015-2024-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
543 Padavano J, Henkhaus RS, Chen H, Skovan BA, Cui H, Ignatenko NA. Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways. Cancer Growth Metastasis 2015;8:95-113. [PMID: 26512205 DOI: 10.4137/CGM.S29407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
544 Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer. 2007;96:457-463. [PMID: 17224927 DOI: 10.1038/sj.bjc. 6603559] [Reference Citation Analysis]
545 Satoi S, Yanagimoto H, Yamamoto T, Toyokawa H, Hirooka S, Yamaki S, Opendro SS, Inoue K, Michiura T, Ryota H, Matsui Y, Kon M. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. World J Surg Oncol 2016;14:14. [PMID: 26791083 DOI: 10.1186/s12957-016-0767-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
546 Takahashi M, Yoshitomi H, Kato A, Furukawa K, Takayashiki T, Kuboki S, Takano S, Sugiura K, Kawasaki K, Miyazaki M, Ohtsuka M. A case of successfully resected metachronous gastric and gallbladder metastases from pancreatic body cancer.Surg Case Rep. 2019;5:21. [PMID: 30758733 DOI: 10.1186/s40792-019-0581-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
547 Cruz-Monserrate Z, Qiu S, Evers BM, O’Connor KL. Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod Pathol. 2007;20:656-667. [PMID: 17415382 DOI: 10.1038/modpathol.3800782] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
548 Tjomsland V, Spångeus A, Välilä J, Sandström P, Borch K, Druid H, Falkmer S, Falkmer U, Messmer D, Larsson M. Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 2011;13:664-75. [PMID: 21847358 DOI: 10.1593/neo.11332] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 6.6] [Reference Citation Analysis]
549 Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM, Sarkar FH. Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM). Pharm Res 2008;25:2117-24. [PMID: 18427961 DOI: 10.1007/s11095-008-9581-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
550 Im HJ, Oo S, Jung W, Jang JY, Kim SW, Cheon GJ, Kang KW, Chung JK, Kim EE, Lee DS. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer. Medicine (Baltimore) 2016;95:e3686. [PMID: 27175707 DOI: 10.1097/MD.0000000000003686] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
551 Guo S, Fesler A, Huang W, Wang Y, Yang J, Wang X, Zheng Y, Hwang GR, Wang H, Ju J. Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma. Mol Ther Nucleic Acids 2020;19:228-39. [PMID: 31846800 DOI: 10.1016/j.omtn.2019.11.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
552 Stadel D, Cristofanon S, Abhari BA, Deshayes K, Zobel K, Vucic D, Debatin KM, Fulda S. Requirement of nuclear factor κB for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis. Neoplasia 2011;13:1162-70. [PMID: 22241962 DOI: 10.1593/neo.11460] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
553 Lozanovski VJ, Houben P, Hinz U, Hackert T, Herr I, Schemmer P. Pilot study evaluating broccoli sprouts in advanced pancreatic cancer (POUDER trial) - study protocol for a randomized controlled trial. Trials 2014;15:204. [PMID: 24894410 DOI: 10.1186/1745-6215-15-204] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
554 Nomura S, Yoshitomi H, Takano S, Shida T, Kobayashi S, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, Miyazaki M. FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer. Br J Cancer. 2008;99:305-313. [PMID: 18594526 DOI: 10.1038/sj.bjc.6604473] [Cited by in Crossref: 85] [Cited by in F6Publishing: 72] [Article Influence: 6.5] [Reference Citation Analysis]
555 Rong Y, Qin X, Jin D, Lou W, Wu L, Wang D, Wu W, Ni X, Mao Z, Kuang T. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin Exp Med. 2012;12:173-180. [PMID: 21932124 DOI: 10.1007/s10238-011-0159-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
556 Kitano A, Shimasaki T, Chikano Y, Nakada M, Hirose M, Higashi T, Ishigaki Y, Endo Y, Takino T, Sato H, Sai Y, Miyamoto K, Motoo Y, Kawakami K, Minamoto T. Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. PLoS One 2013;8:e55289. [PMID: 23408967 DOI: 10.1371/journal.pone.0055289] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
557 Chang J, Tian J, Zhu Y, Zhong R, Zhai K, Li J, Ke J, Han Q, Lou J, Chen W, Zhu B, Shen N, Zhang Y, Gong Y, Yang Y, Zou D, Peng X, Zhang Z, Zhang X, Huang K, Yang M, Wang L, Wu C, Lin D, Miao X. Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations. Nat Commun 2018;9:3688. [PMID: 30206226 DOI: 10.1038/s41467-018-06136-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
558 Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol. 2014;20:10740-10751. [PMID: 25152577 DOI: 10.3748/wjg.v20.i31.10740] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 58] [Article Influence: 13.7] [Reference Citation Analysis]
559 Zhang J, Liu C, Mo X, Shi H, Li S. Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer. Oncol Lett 2018;15:1771-6. [PMID: 29434873 DOI: 10.3892/ol.2017.7512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
560 Schaeffer DF, Assi K, Chan K, Buczkowski AK, Chung SW, Scudamore CH, Weiss A, Salh B, Owen DA. Tumor expression of integrin-linked kinase (ILK) correlates with the expression of the E-cadherin repressor snail: an immunohistochemical study in ductal pancreatic adenocarcinoma. Virchows Arch. 2010;456:261-268. [PMID: 20091050 DOI: 10.1007/s00428-009-0866-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
561 Deeb D, Gao X, Liu YB, Pindolia K, Gautam SC. Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2. Int J Oncol 2014;44:1707-15. [PMID: 24603988 DOI: 10.3892/ijo.2014.2325] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 7.1] [Reference Citation Analysis]
562 Wang Z, Tian YP. Clinical value of serum tumor markers CA19-9, CA125 and CA72-4 in the diagnosis of pancreatic carcinoma. Mol Clin Oncol 2014;2:265-8. [PMID: 24649344 DOI: 10.3892/mco.2013.226] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
563 Kumar SA, Thakur C, Li L, Cui H, Chen F. Pathological and prognostic role of mdig in pancreatic cancer. Genes Cancer 2017;8:650-8. [PMID: 28966726 DOI: 10.18632/genesandcancer.149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
564 Zhong J, Patel K, Switchenko J, Cassidy RJ, Hall WA, Gillespie T, Patel PR, Kooby D, Landry J. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 2017;123:3486-3493. [PMID: 28493288 DOI: 10.1002/cncr.30706] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 12.5] [Reference Citation Analysis]
565 Brand RE, Greer JB, Zolotarevsky E, Brand R, Du H, Simeone D, Zisman A, Gorchow A, Lee SY, Roy HK. Pancreatic cancer patients who smoke and drink are diagnosed at younger ages. Clin Gastroenterol Hepatol. 2009;7:1007-1012. [PMID: 19560558 DOI: 10.1016/j.cgh.2009.06.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
566 Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balakrishna S, Ellis RT, Thompson PA, Balabathula P, Behrman SW, Zafar N, Singh MM, Halaweish FT, Jaggi M, Chauhan SC. Nanoparticle formulation of ormeloxifene for pancreatic cancer. Biomaterials 2015;53:731-43. [PMID: 25890768 DOI: 10.1016/j.biomaterials.2015.02.082] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
567 Yokoi K, Sasaki T, Bucana CD, Fan D, Baker CH, Kitadai Y, Kuwai T, Abbruzzese JL, Fidler IJ. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res. 2005;65:10371-10380. [PMID: 16288027 DOI: 10.1158/0008-5472.can-05-1698] [Cited by in Crossref: 73] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
568 Li Y, Karagöz GE, Seo YH, Zhang T, Jiang Y, Yu Y, Duarte AM, Schwartz SJ, Boelens R, Carroll K, Rüdiger SG, Sun D. Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90. J Nutr Biochem 2012;23:1617-26. [PMID: 22444872 DOI: 10.1016/j.jnutbio.2011.11.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
569 Nasher O, Hall NJ, Sebire NJ, de Coppi P, Pierro A. Pancreatic tumours in children: diagnosis, treatment and outcome. Pediatr Surg Int. 2015;31:831-835. [PMID: 26174862 DOI: 10.1007/s00383-015-3727-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
570 Lucenteforte E, La Vecchia C, Silverman D, Petersen GM, Bracci PM, Ji BT, Bosetti C, Li D, Gallinger S, Miller AB. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012;23:374-382. [PMID: 21536662 DOI: 10.1093/annonc/mdr120] [Cited by in Crossref: 124] [Cited by in F6Publishing: 97] [Article Influence: 12.4] [Reference Citation Analysis]
571 Kang JH, Jung MY, Leof EB. B7-1 drives TGF-β stimulated pancreatic carcinoma cell migration and expression of EMT target genes. PLoS One 2019;14:e0222083. [PMID: 31483844 DOI: 10.1371/journal.pone.0222083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
572 Zogopoulos G, Rothenmund H, Eppel A, Ash C, Akbari MR, Hedley D, Narod SA, Gallinger S. The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Hum Genet 2007;121:635-7. [PMID: 17415588 DOI: 10.1007/s00439-007-0361-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
573 Guerra C, Barbacid M. Genetically engineered mouse models of pancreatic adenocarcinoma. Mol Oncol 2013;7:232-47. [PMID: 23506980 DOI: 10.1016/j.molonc.2013.02.002] [Cited by in Crossref: 102] [Cited by in F6Publishing: 92] [Article Influence: 12.8] [Reference Citation Analysis]
574 Wang BS, Liu Z, Sun SL, Zhao Y. Identification of genes and candidate agents associated with pancreatic cancer. Tumour Biol 2014;35:81-8. [PMID: 23934415 DOI: 10.1007/s13277-013-1009-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
575 Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, Chen Q. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med 2011;50:1610-9. [PMID: 21402145 DOI: 10.1016/j.freeradbiomed.2011.03.007] [Cited by in Crossref: 97] [Cited by in F6Publishing: 92] [Article Influence: 9.7] [Reference Citation Analysis]
576 Saif MW, Karapanagiotou L, Syrigos K. Genetic alterations in pancreatic cancer. World J Gastroenterol 2007;13:4423-30. [PMID: 17724796 DOI: 10.3748/wjg.v13.i33.4423] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
577 Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H, Nakajima Y. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009;101:1709-16. [PMID: 19844235 DOI: 10.1038/sj.bjc.6605375] [Cited by in Crossref: 100] [Cited by in F6Publishing: 92] [Article Influence: 8.3] [Reference Citation Analysis]
578 Navas C, Hernández-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22:318-330. [PMID: 22975375 DOI: 10.1016/j.ccr.2012.08.001] [Cited by in Crossref: 247] [Cited by in F6Publishing: 218] [Article Influence: 27.4] [Reference Citation Analysis]
579 Doi C, Maurya DK, Pyle MM, Troyer D, Tamura M. Cytotherapy with naive rat umbilical cord matrix stem cells significantly attenuates growth of murine pancreatic cancer cells and increases survival in syngeneic mice. Cytotherapy. 2010;12:408-417. [PMID: 20345214 DOI: 10.3109/14653240903548194] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
580 Martinez-Useros J, Garcia-Foncillas J. Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? Biomed Res Int 2016;2016:4873089. [PMID: 27689078 DOI: 10.1155/2016/4873089] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
581 Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer. 2007;96:457-463. [PMID: 17224927 DOI: 10.1038/sj.bjc.6603559] [Cited by in Crossref: 190] [Cited by in F6Publishing: 183] [Article Influence: 13.6] [Reference Citation Analysis]
582 Chen J, Xu H, Zou X, Wang J, Zhu Y, Chen H, Shen B, Deng X, Zhou A, Chin YE. Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells. Cancer Res. 2014;74:4353-4363. [PMID: 24903147 DOI: 10.1158/0008-5472.CAN-14-0181] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 6.9] [Reference Citation Analysis]
583 Deeb D, Gao X, Liu Y, Pindolia K, Gautam SC. Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells. Oncol Rep 2015;34:518-24. [PMID: 25997419 DOI: 10.3892/or.2015.3989] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
584 Avery JT, Zhang R, Boohaker RJ. GLI1: A Therapeutic Target for Cancer. Front Oncol 2021;11:673154. [PMID: 34113570 DOI: 10.3389/fonc.2021.673154] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
585 Flook R, van Zanten SV. Pancreatic cancer in Canada: incidence and mortality trends from 1992 to 2005. Can J Gastroenterol 2009;23:546-50. [PMID: 19668798 DOI: 10.1155/2009/986531] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
586 Liu QQ, Chen K, Ye Q, Jiang XH, Sun YW. Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling pathway. Cancer Cell Int. 2016;16:57. [PMID: 27453691 DOI: 10.1186/s12935-016-0336-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
587 Tsai HJ, Chang JS. Environmental Risk Factors of Pancreatic Cancer. J Clin Med. 2019;8. [PMID: 31510046 DOI: 10.3390/jcm8091427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
588 Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One. 2011;6:e20636. [PMID: 21695188 DOI: 10.1371/journal.pone.0020636] [Cited by in Crossref: 180] [Cited by in F6Publishing: 185] [Article Influence: 18.0] [Reference Citation Analysis]
589 Soltek S, Karakhanova S, Golovastova M, D'Haese JG, Serba S, Nachtigall I, Philippov PP, Werner J, Bazhin AV. Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma. Naunyn Schmiedebergs Arch Pharmacol 2015;388:1121-8. [PMID: 26105003 DOI: 10.1007/s00210-015-1147-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
590 Luo B, Wang J, Li X, Lu W, Yang J, Hu Y, Huang P, Wen S. New Mild and Simple Approach to Isothiocyanates: A Class of Potent Anticancer Agents. Molecules 2017;22:E773. [PMID: 28587167 DOI: 10.3390/molecules22060773] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
591 Silviu UB, Daniel P, Claudiu M, Săndulescu L, Simona F, Ştefan P, Valeriu Ş, Adrian S. Endoscopic ultrasound-guided radiofrequency ablation of the pancreas: An experimental study with pathological correlation. Endosc Ultrasound 2015;4:330-5. [PMID: 26643702 DOI: 10.4103/2303-9027.170426] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
592 Park H, Bang JH, Nam AR, Park JE, Jin MH, Bang YJ, Oh DY. The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy. Cancer Med 2020;9:43-51. [PMID: 31701645 DOI: 10.1002/cam4.2677] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
593 Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford) 2008;10:58-62. [PMID: 18695761 DOI: 10.1080/13651820701883148] [Cited by in Crossref: 221] [Cited by in F6Publishing: 190] [Article Influence: 20.1] [Reference Citation Analysis]
594 Buchs NC, Chilcott M, Poletti PA, Buhler LH, Morel P. Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management. World J Gastroenterol. 2010;16:818-831. [PMID: 20143460 DOI: 10.3748/wjg.v16.i7.818] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
595 Takhar AS, Palaniappan P, Dhingsa R, Lobo DN. Recent developments in diagnosis of pancreatic cancer. BMJ. 2004;329:668-673. [PMID: 15374918 DOI: 10.1136/bmj.329.7467.668] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
596 Liu Z, Meng J, Quinn KP, Georgakoudi I. Tissue Imaging and Quantification Relying on Endogenous Contrast. Adv Exp Med Biol 2021;3233:257-88. [PMID: 34053031 DOI: 10.1007/978-981-15-7627-0_12] [Reference Citation Analysis]
597 Li T, Wang Z, Hou YF, Li YY. Pim-3 Regulates Stemness of Pancreatic Cancer Cells via Activating STAT3 Signaling Pathway. J Cancer 2017;8:1530-41. [PMID: 28775772 DOI: 10.7150/jca.18628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
598 Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol. 2009;174:854-868. [PMID: 19179606 DOI: 10.2353/ajpath.2009.080523] [Cited by in Crossref: 130] [Cited by in F6Publishing: 120] [Article Influence: 10.8] [Reference Citation Analysis]
599 Chen L, Fan J, Chen H, Meng Z, Chen Z, Wang P, Liu L. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Sci Rep. 2014;4:5911. [PMID: 25081383 DOI: 10.1038/srep05911] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 11.6] [Reference Citation Analysis]
600 Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, Lele SM, Ouellette M, Pour PM, Sasson AR. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer. 2008;98:1540-1547. [PMID: 18392050 DOI: 10.1038/sj.bjc.6604329] [Cited by in Crossref: 111] [Cited by in F6Publishing: 100] [Article Influence: 8.5] [Reference Citation Analysis]
601 Immervoll H, Hoem D, Kugarajh K, Steine SJ, Molven A. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch 2006;448:788-96. [PMID: 16598499 DOI: 10.1007/s00428-006-0191-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
602 Sadanandam A, Varney ML, Singh S, Ashour AE, Moniaux N, Deb S, Lele SM, Batra SK, Singh RK. High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. Int J Cancer 2010;127:1373-83. [PMID: 20073063 DOI: 10.1002/ijc.25166] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
603 Walters DM, Lapar DJ, de Lange EE, Sarti M, Stokes JB, Adams RB, Bauer TW. Pancreas-protocol imaging at a high-volume center leads to improved preoperative staging of pancreatic ductal adenocarcinoma. Ann Surg Oncol 2011;18:2764-71. [PMID: 21484522 DOI: 10.1245/s10434-011-1693-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
604 Du X, Xiang L, Mackall C, Pastan I. Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody. Clin Cancer Res 2011;17:5926-34. [PMID: 21813632 DOI: 10.1158/1078-0432.CCR-11-1235] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
605 Nilsson HO, Stenram U, Ihse I, Wadstrom T. Helicobacter species ribosomal DNA in the pancreas, stomach and duodenum of pancreatic cancer patients. World J Gastroenterol. 2006;12:3038-3043. [PMID: 16718784 DOI: 10.3748/wjg.v12.i19.3038] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.0] [Reference Citation Analysis]
606 Gong DJ, Zhang JM, Yu M, Zhuang B, Guo QQ. Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma. Clin Interv Aging. 2013;8:889-897. [PMID: 23898224 DOI: 10.2147/cia.s45064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
607 Kalinina T, Güngör C, Thieltges S, Möller-Krull M, Penas EM, Wicklein D, Streichert T, Schumacher U, Kalinin V, Simon R. Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. BMC Cancer. 2010;10:295. [PMID: 20553613 DOI: 10.1186/1471-2407-10-295] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
608 Roy R, Zurakowski D, Wischhusen J, Frauenhoffer C, Hooshmand S, Kulke M, Moses MA. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer. 2014;111:1772-1779. [PMID: 25137018 DOI: 10.1038/bjc.2014.462] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
609 Kuroczycki-Saniutycz S, Grzeszczuk A, Zwierz ZW, Kołodziejczyk P, Szczesiul J, Zalewska-Szajda B, Ościłowicz K, Waszkiewicz N, Zwierz K, Szajda SD. Prevention of pancreatic cancer. Contemp Oncol (Pozn) 2017;21:30-4. [PMID: 28435395 DOI: 10.5114/wo.2016.63043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
610 Zhang Y, Xu G, Chen M, Wei Q, Zhou T, Chen Z, Shen M, Wang P. Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study. Front Oncol 2020;10:1018. [PMID: 32766130 DOI: 10.3389/fonc.2020.01018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
611 Gleason MX, Mdzinarishvili T, Are C, Sasson A, Sherman A, Shats O, Sherman S. Prognostic estimator of survival for patients with localized and extended pancreatic ductal adenocarcinoma. Cancer Inform 2013;12:103-14. [PMID: 23589669 DOI: 10.4137/CIN.S11496] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
612 Zhou PT, Li B, Liu FR, Zhang MC, Wang Q, Li YY, Xu C, Liu YH, Yao Y, Li D. Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. Oncotarget 2017;8:25242-50. [PMID: 28445955 DOI: 10.18632/oncotarget.15692] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
613 Chen Q, Ning Z, Wang L, Ying H, Dong S, Zhang C, Shen X, Guo Y, Chen H, Zhu X, Shen Y, Shi W, Hua Y, Wang K, Lin J, Xu L, Chen L, Feng L, Zhang X, Xie J, Sun B, Sun Y, Gu W, Kang M, Tang Z, Chen Z, Chen Z, Liu L, Yu J, Li Z, Meng Z. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study. Oncotarget 2016;7:85603-12. [PMID: 27811354 DOI: 10.18632/oncotarget.13000] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
614 Gailhouste L, Liew LC, Hatada I, Nakagama H, Ochiya T. Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells. Cell Death Dis 2018;9:468. [PMID: 29700299 DOI: 10.1038/s41419-018-0487-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
615 Zhang DX, Dai YD, Yuan SX, Tao L. Prognostic factors in patients with pancreatic cancer. Exp Ther Med. 2012;3:423-432. [PMID: 22969906 DOI: 10.3892/etm.2011.412] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
616 Danovi SA, Wong HH, Lemoine NR. Targeted therapies for pancreatic cancer. Br Med Bull. 2008;87:97-130. [PMID: 18753179 DOI: 10.1093/bmb/ldn027] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
617 Lin F, Wang X, Jie Z, Hong X, Li X, Wang M, Yu Y. Inhibitory effects of miR-146b-5p on cell migration and invasion of pancreatic cancer by targeting MMP16. J Huazhong Univ Sci Technolog Med Sci 2011;31:509. [PMID: 21823013 DOI: 10.1007/s11596-011-0481-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
618 Momi N, Kaur S, Ponnusamy MP, Kumar S, Wittel UA, Batra SK. Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis. Carcinogenesis 2012;33:1617-28. [PMID: 22623649 DOI: 10.1093/carcin/bgs186] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
619 Yao J, Li WY, Li SG, Feng XS, Gao SG. Midkine promotes perineural invasion in human pancreatic cancer. World J Gastroenterol. 2014;20:3018-3024. [PMID: 24659893 DOI: 10.3748/wjg.v20.i11.3018] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
620 Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y. Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med 2011;2:103-8. [PMID: 22977477 DOI: 10.3892/etm.2010.181] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
621 Ward ST, Dangi-Garimella S, Shields MA, Collander BA, Siddiqui MA, Krantz SB, Munshi HG. Ethanol differentially regulates snail family of transcription factors and invasion of premalignant and malignant pancreatic ductal cells. J Cell Biochem 2011;112:2966-73. [PMID: 21678462 DOI: 10.1002/jcb.23215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
622 Quan M, Wang P, Cui J, Gao Y, Xie K. The roles of FOXM1 in pancreatic stem cells and carcinogenesis. Mol Cancer 2013;12:159. [PMID: 24325450 DOI: 10.1186/1476-4598-12-159] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
623 Huang W, Li N, Hu J, Wang L. Inhibitory effect of RNA-mediated knockdown of zinc finger protein 91 pseudogene on pancreatic cancer cell growth and invasion. Oncol Lett 2016;12:1343-8. [PMID: 27446435 DOI: 10.3892/ol.2016.4794] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
624 Ohmine K, Kawaguchi K, Ohtsuki S, Motoi F, Egawa S, Unno M, Terasaki T. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells. Pharm Res 2012;29:2006-16. [PMID: 22419259 DOI: 10.1007/s11095-012-0728-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
625 Spratlin JL, Chu Q, Koski S, King K, Mulder K. Targeting metastatic upper gastrointestinal adenocarcinomas. World J Clin Oncol 2011;2:135-49. [PMID: 21611088 DOI: 10.5306/wjco.v2.i3.135] [Cited by in CrossRef: 2] [Article Influence: 0.2] [Reference Citation Analysis]
626 Yang J, Li J, Zhu R, Zhang H, Zheng Y, Dai W, Wang F, Shen M, Chen K, Cheng P, Zhang Y, Wang C, Wang J, Xia Y, Lu J, Zhou Y, Guo C. K-ras mutational status in cytohistological tissue as a molecular marker for the diagnosis of pancreatic cancer: a systematic review and meta-analysis. Dis Markers 2014;2014:573783. [PMID: 25301978 DOI: 10.1155/2014/573783] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
627 Muñoz M, Coveñas R. Involvement of substance P and the NK-1 receptor in pancreatic cancer. World J Gastroenterol 2014;20:2321-34. [PMID: 24605029 DOI: 10.3748/wjg.v20.i9.2321] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
628 Venkatesulu BP, Hsieh CE, Sanders KL, Krishnan S. Recent advances in radiation therapy of pancreatic cancer. F1000Res 2018;7:F1000 Faculty Rev-1931. [PMID: 30613390 DOI: 10.12688/f1000research.16272.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
629 Li L, Zhang GQ, Chen H, Zhao ZJ, Chen HZ, Liu H, Wang G, Jia YH, Pan SH, Kong R, Wang YW, Sun B. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Oncotarget. 2016;7:71773-71781. [PMID: 27708234 DOI: 10.18632/oncotarget.12365] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
630 Lodestijn SC, van Neerven SM, Vermeulen L, Bijlsma MF. Stem Cells in the Exocrine Pancreas during Homeostasis, Injury, and Cancer. Cancers (Basel) 2021;13:3295. [PMID: 34209288 DOI: 10.3390/cancers13133295] [Reference Citation Analysis]
631 Saukkonen K, Hagström J, Mustonen H, Juuti A, Nordling S, Fermér C, Nilsson O, Seppänen H, Haglund C. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma. PLoS One 2015;10:e0129012. [PMID: 26053486 DOI: 10.1371/journal.pone.0129012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
632 Wang L, Barth CW, Sibrian-Vazquez M, Escobedo JO, Lowry M, Muschler J, Li H, Gibbs SL, Strongin RM. Far-Red and Near-Infrared Seminaphthofluorophores for Targeted Pancreatic Cancer Imaging. ACS Omega 2017;2:154-63. [PMID: 28180189 DOI: 10.1021/acsomega.6b00403] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
633 van der Zee JA, van Eijck CH, Hop WC, Biermann K, Dicheva BM, Seynhaeve AL, Koning GA, Eggermont AM, Ten Hagen TL. Tumour basement membrane laminin expression predicts outcome following curative resection of pancreatic head cancer. Br J Cancer 2012;107:1153-8. [PMID: 22929879 DOI: 10.1038/bjc.2012.373] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
634 Guo S, Fesler A, Wang H, Ju J. microRNA based prognostic biomarkers in pancreatic Cancer. Biomark Res 2018;6:18. [PMID: 29942514 DOI: 10.1186/s40364-018-0131-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
635 Chung HW, Lim JB. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma. J Transl Med. 2014;12:102. [PMID: 24745825 DOI: 10.1186/1479-5876-12-102] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
636 Kuo TL, Weng CC, Kuo KK, Chen CY, Wu DC, Hung WC, Cheng KH. APC haploinsufficiency coupled with p53 loss sufficiently induces mucinous cystic neoplasms and invasive pancreatic carcinoma in mice. Oncogene 2016;35:2223-34. [PMID: 26411367 DOI: 10.1038/onc.2015.284] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
637 Kim Y, Han D, Min H, Jin J, Yi EC, Kim Y. Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines. Mol Cells. 2014;37:888-898. [PMID: 25518923 DOI: 10.14348/molcells.2014.0207] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
638 Liu C, Lu Y, Luo G, Cheng H, Guo M, Liu Z, Xu J, Long J, Liu L, Fu D. Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer? Oncotarget. 2016;7:29177-29186. [PMID: 27081079 DOI: 10.18632/oncotarget.8690] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
639 Li Z, Zhao X, Zhou Y, Liu Y, Zhou Q, Ye H, Wang Y, Zeng J, Song Y, Gao W. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. J Transl Med. 2015;13:84. [PMID: 25889214 DOI: 10.1186/s12967-015-0442-z] [Cited by in Crossref: 145] [Cited by in F6Publishing: 145] [Article Influence: 24.2] [Reference Citation Analysis]
640 Marley AR, Fan H, Hoyt ML, Anderson KE, Zhang J. Intake of methyl-related nutrients and risk of pancreatic cancer in a population-based case-control study in Minnesota. Eur J Clin Nutr 2018;72:1128-35. [PMID: 29904184 DOI: 10.1038/s41430-018-0228-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
641 Schäfer C, Seeliger H, Bader DC, Assmann G, Buchner D, Guo Y, Ziesch A, Palagyi A, Ochs S, Laubender RP. Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2012;16:1776-1791. [PMID: 22004109 DOI: 10.1111/j.1582-4934.2011.01473.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
642 Kwei KA, Shain AH, Bair R, Montgomery K, Karikari CA, van de Rijn M, Hidalgo M, Maitra A, Bashyam MD, Pollack JR. SMURF1 amplification promotes invasiveness in pancreatic cancer. PLoS One 2011;6:e23924. [PMID: 21887346 DOI: 10.1371/journal.pone.0023924] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
643 Baghbanian M, Salmanroghani H, Baghbanian A, Bakhtpour M, Shabazkhani B. Resectability of the pancreatic adenocarcinoma: A study from Iran. Adv Biomed Res 2014;3:265. [PMID: 25625104 DOI: 10.4103/2277-9175.148246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
644 Zhao F, Vermeer B, Lehmann U, Kreipe H, Manns MP, Korangy F, Greten TF. Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma. Immunology 2009;128:134-40. [PMID: 19689742 DOI: 10.1111/j.1365-2567.2009.03090.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
645 Polireddy K, Chen Q. Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. J Cancer 2016;7:1497-514. [PMID: 27471566 DOI: 10.7150/jca.14922] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
646 Chen Y, Shi M, Yu GZ, Qin XR, Jin G, Chen P, Zhu MH. Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol. 2012;18:1123-1129. [PMID: 22416189 DOI: 10.3748/wjg.v18.i10.1123] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 56] [Article Influence: 7.2] [Reference Citation Analysis]
647 Rong Y, Jin D, Wu W, Lou W, Wang D, Kuang T, Ni X, Qin X. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer. 2009;9:191. [PMID: 19534821 DOI: 10.1186/1471-2407-9-191] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
648 Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012;20:749-58. [PMID: 22186794 DOI: 10.1038/mt.2011.276] [Cited by in Crossref: 145] [Cited by in F6Publishing: 138] [Article Influence: 14.5] [Reference Citation Analysis]
649 Song SD, Zhou J, Zhou J, Zhao H, Cen JN, Li DC. MicroRNA-375 targets the 3-phosphoinositide-dependent protein kinase-1 gene in pancreatic carcinoma. Oncol Lett. 2013;6:953-959. [PMID: 24137444 DOI: 10.3892/ol.2013.1510] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
650 Senapati S, Gnanapragassam VS, Moniaux N, Momi N, Batra SK. Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells. Oncogene 2012;31:3346-56. [PMID: 22105367 DOI: 10.1038/onc.2011.505] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
651 Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol. 2014;20:7864-7877. [PMID: 24976723 DOI: 10.3748/wjg.v20.i24.7864] [Cited by in CrossRef: 186] [Cited by in F6Publishing: 136] [Article Influence: 31.0] [Reference Citation Analysis]